

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Efficacy and safety of GHX02 in the treatment of acute bronchitis: protocol of a phase 2, double-blind, randomized placebo-controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019897
Article Type:	Protocol
Date Submitted by the Author:	03-Oct-2017
Complete List of Authors:	Lyu, Yee Ran; College of Korean Medicine, Daejeon University, Division of Respiratory System, Dept. of Internal Medicine Yang, Won-Kyung ; Institute of Traditional Medicine and Bioscience, Daejeon University Park, So Jung ; Dunsan Korean Medicine Hospital of Daejeon University, East West Cancer Center Kim, Seung-Hyeong; Institute of Traditional Medicine and Bioscience, Daejeon University Kang, Wee-Chang; College of Economics, Daejeon University, Dept. of Applicative Statistics Jung, In Chul; College of Korean Medicine, Daejeon University, Dept. of Neuropsychology Park, Yang Chun; College of Korean Medicine, Daejeon University, Division of Respiratory System, Dept. of Internal Medicine
Keywords:	acute bronchitis, Herbal medicine < THERAPEUTICS, GHX02, randomized controlled trial

SCHOLARONE™
Manuscripts

1
2
3
4 **Efficacy and safety of GHX02 in the treatment of acute bronchitis:**
5
6 **protocol of a phase 2, double-blind, randomized placebo-**
7 **controlled trial**
8
9

10
11
12
13 Yee Ran Lyu¹, Won-Kyung Yang^{1, 3}, So Jung Park², Seung-Hyeong Kim³,
14 Wee-Chang Kang⁴, In Chul Jung⁵, Yang Chun Park^{1*}
15

16
17
18 ¹ Division of Respiratory System, Dept. of Internal Medicine, College of Korean Medicine, Daejeon
19 University
20

21 ² East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University
22

23 ³ Institute of Traditional Medicine and Bioscience, Daejeon University
24

25 ⁴ Dept. of Applicative Statistics, College of Economics, Daejeon University
26

27 ⁵ Dept. of Neuropsychology, College of Korean Medicine, Daejeon University
28

29 **Correspondence to**

30 Professor Yang-Chun Park, omdpvc@dju.kr

31 Korean Internal Medicine and Director of the Clinical Trial Center

32 Dunsan Korean Medicine Hospital of Daejeon University

33 75, Daedeok-daero 176-beongil, Seo-gu, Daejeon, Republic of Korea 35235

34 Tel: 82-42-470-9126 (clinic), 82-42-229-6763 (office, Munchang Campus)

35 Fax: 82-42-470-9486
36
37
38
39
40

41 Word count : 3692
42
43
44
45
46
47
48
49
50
51
52
53
54

ABSTRACT

Introduction: Acute bronchitis is a self-limiting infection of the large airways; cough is the primary symptom, usually lasting for about 3 weeks. Annually, approximately 5% of adults develop acute bronchitis, and its economic burden is substantial. There are also problems of antibiotic abuse associated with the treatment of acute bronchitis in public health systems, despite up to 90% of acute bronchitis cases being caused by viruses. Symptomatic therapies are commonly prescribed, for which there is insufficient supporting evidence. GHX02 contains four herbs originating from *gualouhengryunhwan*, which has been used in the treatment of acute bronchitis patients in Korea. The objective is to compare the GHX02 and placebo in terms of efficacy and safety, and to determine the appropriate dosage.

Methods and analysis: We planned a phase 2, multicentre, dose-finding, double-blind, randomized placebo-controlled trial of two different doses of GHX02 compared with placebo. A total of 150 patients, aged between 17 and 75, with a Bronchitis Severity Score (BSS) ≥ 5 due to acute bronchitis starting within 2 weeks of study enrolment will be recruited from three university-affiliated hospitals across Korea. Participants will be randomly assigned to either a high-dose GHX02 group (1,920mg/day), a standard-dose GHX02 group (960mg/day), or a placebo group according to a 1:1:1 allocation ratio using stratification block randomization with pattern identification. Patients will take medications three times daily for 7 days, with 3 visiting days. The primary outcome measure is a change in BSS from day 0 to day 7. The secondary outcomes are the Questionnaire of Clinical Symptoms of Cough and Sputum, Leicester Cough Questionnaire, frequency of coughing fits, Integrative Medicine Outcome Scale and the Integrative Medicine Patient Satisfaction Scale.

Ethics and dissemination: The study has been approved by our Institutional Review Board. (No. DJDSKH-17-DR-14) The trial results will be disseminated via peer-reviewed journals and the Clinical Research Information Service. Trial registration: NCT03310385

KEY WORDS: acute bronchitis, herbal medicine, GHX02, randomized controlled trial

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This study will provide new evidence for the efficacy and safety of GHX02 in a standard

research design

- We will use the Korean Standard Tool of Pattern Identifications of Cough and Sputum, via stratified block randomization
- This is a well-designed study and the outcome measures are well balanced between patients' subjective and objective outcomes
- Multicentre study
- Limitation is that this trial protocol only targets adults

INTRODUCTION

Acute bronchitis is the most common disease seen in outpatient departments (OPDs) across South Korea; about 5% of the general population have acute bronchitis.¹ In 2016, the Health Insurance Review & Assessment Service of South Korea estimated that more than 1500 million people visited OPDs for acute bronchitis and that the rate of increase in medical expenses, compared to that over the previous year, also rose.² Thus, acute bronchitis represents a substantial economic burden on the public health system, and effective therapeutic agents are urgently required.³

Acute bronchitis is a self-limiting infection of the large airways, with cough as the primary symptom, usually lasting for about 3 weeks.⁴ It is characterized by acute onset of cough, accompanied by the production of sputum and dyspnea or chest discomfort.⁵ As there are no specific diagnostic criteria for acute bronchitis, diagnosis is primarily clinical and requires a thorough assessment to differentiate from pneumonia, common cold, and asthma.⁶ Up to 90% of acute bronchitis is caused by viruses; bacterial infection accounts only for less than 10%. Nevertheless, 60–80% of patients, despite evidence of little or no benefit, are treated with antibiotics, contributing to bacterial resistance associated with multiple adverse effects.⁷ Several guidelines and meta-analyses of randomized controlled trials (RCTs) have concluded that antibiotic treatment is mostly ineffective in acute bronchitis, unless the infection is of bacterial origin.⁸

As antibiotics are generally not recommended for acute bronchitis, symptomatic therapy such as antitussives, expectorants, beta-2 agonists, and alternative therapies are commonly prescribed, despite insufficient evidence to support such treatments. There have been the lack of consistent evidence for their use of antitussives on acute bronchitis,⁹ and the evidence regarding the use of expectorants is also questionable.¹⁰ Beta-2 agonists are reported to be effective for patients with airflow obstruction, but adverse events like tremor and nervousness are widely observed.¹¹

Alternative therapies, like *Pelargonium sidodes* or ivy leaf extracts are used in various European countries, with variable results.^{12 13}

Thus, there have been substantial efforts worldwide to develop effective therapeutic agents for treating acute bronchitis. In this study, we focused on herbal medicines that have been used for centuries in Oriental countries; we sought to evaluate the efficacy and safety of GHX02, which contains four herbs originating from *gualouhengryunhwan* (GLHRH) in Donguibogam (Principles and Practice of Eastern Medicine) (Table 1). GHX02 has been used for the treatment of patients with acute bronchitis in the Dunsan Korean Medicine Hospital, Daejeon University, and its effectiveness against acute cough has already been demonstrated. We planned a phase 2, multicentre, dose-finding, double-blind, randomized placebo-controlled trial of two different doses of GHX02 compared with placebo. The objective is to compare the GHX02 and placebo in terms of efficacy and safety, and to determine the appropriate dosage of GHX02 required for the treatment of acute bronchitis. We chose a placebo as the control, as this is the most rigorous test for evaluating the efficacy of new medical therapy in a double-blind RCT.¹⁴ In addition, as acute bronchitis is a self-limiting disorder, placebo control is ethically justifiable.

Table 1. Components of GHX02

Herb	Latin name	Family name	Part of plant	Amount
Gualouin	<i>Trichosanthis Semen</i>	Cucurbitaceae	seed	351mg
Hengin	<i>Armeniaca Semen</i>	Rosaceae	seed	175.5mg
Hwangryun	<i>Coptidis Rhizoma</i>	Ranunculaceae	root stock	175.5mg
Hwangkum	<i>Scutellariae Radix</i>	Labiatae/Lamiaceae	root	351mg

METHODS AND ANALYSIS

Trial Design

This study is a phase 2, multicentre, dose-finding, double-blind, randomized placebo-controlled trial to evaluate the efficacy and safety of two different doses of GHX02, compared with placebo, for acute bronchitis. The trial will be conducted at three university-affiliated hospitals, including the Dunsan Korean Medicine Hospital, Daejeon University; the Kyunghee University Korean

Medicine Hospital; and the Pusan National University Korean Medicine Hospital which have been listed on advertising posters. One-hundred and fifty patients will be included in this trial and randomly assigned to either a high-dose GHX02 group (1920mg/day), standard-dose GHX02 group (960mg/day), or control group (placebo) in a 1:1:1 allocation ratio. Patients will take one of the medications three times a day for 7 days, with 3 visiting days (screening, day0, day7). On the screening day, we will use the Korean Standard Tool of Pattern Identification of Cough and Sputum, a diagnostic system that determines therapy in Traditional Korean Medicine, to allocate patients into three groups of *wind-heat*, *wind-cold* or *others* (Figure1, Table2). This follows the guidelines of the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)¹⁵, Reporting Randomized, Controlled Trials of Herbal Interventions¹⁶ and the trial will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.

Table2. Timetable of study period

TIMEPOINT	STUDY PERIOD			
	Enrolment screening	Allocation Day 0	Post-allocation Day 0 Day 7	
ENROLMENT:				
Eligibility screen	X			
Informed consent	X			
Demographic data	X			
Vital signs	X		X	X
Past history	X			
Concomitant medication	X		X	X
Physical examination & radiography	X			
Laboratory examination	X			X
Pattern identification of cough & sputum	X			
Allocation		X		
INTERVENTIONS:				
High-dose GHX02			←————→	
Standard-dose GHX02			←————→	
Placebo			←————→	
ASSESSMENTS:				
BSS	X		X	X
QCSCS			X	X
LCQ-K-acute			X	X
Frequency of cough fits			←————→	
IMOS, IMPSS				X
Concomitant therapy			X	X

Adverse events			X	X
Compliance				X

BSS, Bronchitis Severity Score; QCSCS, Questionnaire on Clinical Symptoms of Cough & Sputum; LCQ-K-acute, Leicester Cough Questionnaire-Korean version-acute; IMOS, Integrative Medicine Outcome Scale; IMPSS, Integrative Medicine Patient Satisfaction Scale

Study Drug and Placebo

GHX02 is a combination of the following four herbs: Gualouin (*Trichosanthis Semen*, 351 mg/tablet), Hengin (*Armeniacae Semen*, 175.5 mg/tablet), Hwangryun (*Coptidis Rhizoma*, 175.5 mg/tablet), Hwangkum (*Scutellariae Radix*, 351 mg/tablet) (Table 1). One GHX02 tablet (500mg/tablet) contains 160.0mg of dry extract of the four herbs (obtained by boiling in water and then dehydrating) mixed with 340.0mg of starch and lactose. The placebo tablet does not contain any of these active ingredients but is matched in terms of colour, smell, and taste. The dosage was determined according to the Pharmacologically Active Dose (PAD) in expectorant effective tests. Both tablets are green and round and will be provided by Hankookshinyak Corporation (Nonsan, Korea). The manufacturer complies with the provisions of the Regulations on the Safety of Pharmaceuticals and will manage the quality appropriately. Safety and toxicological tests of GHX02 will be conducted simultaneously. All allocated patients will be prescribed 4 tablets of either the clinical medicine or placebo to be administered three times daily for 7 days, and the number of remaining tablets will be recorded on day7 to calculate compliance. To improve compliance, participants will be asked to record their daily dosage in the cough diary. The overall medication compliance during the trial should be at least 75%; if the medication compliance is less than 75%, the participant will be considered inadequate and excluded from the per-protocol (PP) analysis group.

Sample size

According to the previous study, the estimated sample size required for this study is 150 patients (50 patients per group). This estimation is based on the Bronchitis Severity Score (BSS) of 2.3 ± 3.2 (mean \pm standard deviation; day 0-day 7), obtained from an earlier study.¹⁷ Moreover, to provide 90% power with a two-tailed level of significance of 5% at a ratio of 1:1:1 and dropout rate of 20%, we plan to include 150 patients.

Recruitment

Participants will be recruited from the outpatient departments (OPDs) of the affiliated hospitals and through poster advertisements. Recruitment will commence in January 2018.

Participants

Inclusion criteria

Potential participants who meet the following criteria will be included in this trial: (1) age 19–75 years; (2) BSS \geq 5 points at day0 due to acute bronchitis; (3) symptoms starting within 2 weeks before study inclusion; (4) patients who consent to participate. Diagnoses of acute bronchitis will be based on patients' medical history, physical examinations, and BSS, including cough, sputum, dyspnea, chest pain during coughing, and rales on auscultation.

Exclusion criteria

Patients with any of the following criteria will be excluded from this trial: (1) pregnant or breast-feeding; (2) treatment with antibiotics, bronchodilators, glucocorticoids, immune-depressants, or other clinical trial medicines during the last 4 weeks before study inclusion; (3) treatment with antitussives or expectorants during the last 7 days before study inclusion; (4) history or presence of confounding respiratory disease that may affect evaluation of the efficacy of clinical medicine (e.g. chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, asthma, pneumonia, cystic fibrosis, lung cancer, or active pulmonary tuberculosis); (5) liver or renal impairment (alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase [ALP] \geq 2 times the normal upper limit, or creatinine $>$ 3.0 mg/dL at screening); (6) history or presence of clinically relevant cardiovascular, renal, metabolic, haematological, neurological, psychiatric, systemic, infectious disease, or malignant tumour (except where there is no recurrence for more than 5 years after surgery); (7) history of alcoholism or substance abuse; (8) participation in other clinical medicine trials during the last 30 days before study inclusion; (9) judged by the investigators to be inappropriate for the clinical trial. Additional treatment will not

1
2
3
4 be permitted during the trial, and participants are recommended not to alter their exercise pattern
5 or diet. Drugs that may affect bronchitis symptoms or that have a similar therapeutic purpose to
6 the trial medication will not be permitted, including antibiotics, bronchodilators, glucocorticoids,
7 immune-depressants, antitussives, expectorants, antihistamines, or any other clinical trial medicine.
8 Other medications will only be permitted at the discretion of the investigators. All drug
9 information (name of product, purpose of administration, dosage, duration of administration, etc.)
10 will be recorded on the patient case report form (CRF).
11
12
13
14
15
16
17

18 Randomization and allocation concealment

19
20 Randomization will be conducted by an independent statistician, using a computer random
21 number generator of SAS[®] Analytics Pro (SAS Institute, Inc., Cary, North Carolina, USA). The
22 generated randomization numbers will be concealed using sequentially numbered, opaque, sealed
23 envelopes. Stratified block randomization using the Korean Standard Tool of Pattern Identifications
24 of Cough and Sputum will be performed in this trial. We will allocate three groups (*wind-heat*,
25 *wind-cold*, or *others*) at a 1:1:1 ratio of high-dose, standard-dose, and placebo treatment.
26 Allocation will be implemented by a management pharmacist with no other trial involvement to
27 ensure that neither the participants nor the investigators can foresee group allocation. After
28 participants are deemed eligible, investigators will inform the management pharmacist.
29 Participants will then be given an envelope according to their screening sequential number and
30 assigned to either the intervention or control group.
31
32
33
34
35
36
37
38
39
40

41 *Korean Standard Tool of Pattern Identifications of Cough and Sputum*

42
43 The Korean Standard Tool of Pattern Identifications of Cough and Sputum is used to identify
44 patterns of acute bronchitis patients. It was proposed in the Traditional Korean Medicine Clinical
45 Practice Guidelines for Antitussives and Expectorants for Korean Medical Diagnostic Standards.
46 This comprises 56 items to classify cases into three patterns: *wind-cold*, *wind-heat* or *others*. We
47 will investigate the correlation between the patterns and the efficacy of GHX02.
48
49
50
51
52
53
54

Blinding

This is a double-blind trial, thus neither participants nor investigators (including outcome assessors) will be aware of group assignment until the end of the study period. Placebo tablets will be matched to GHX02 tablets in terms of colour, taste, and smell, as well as outer packaging. Elimination of blindness will only be considered in cases of serious medical emergencies.

Outcome measures

Primary outcome

Bronchitis Severity Score

The BSS was developed as an evaluation tool for acute bronchitis in 1996 and was recently shown to be valid and reliable by the European Medicines Agency's Committee on Herbal Medicinal Products (HMPC).¹⁵ It has been used successfully in many clinical trials for acute bronchitis. BSS comprises the sum of five major symptom scores for acute bronchitis: cough, sputum, dyspnea, chest pain during coughing, and rales on auscultation. Each symptom is scored on a 4-point-scale (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe), with a maximum total score of 20 points. The investigator assesses symptom scores on the basis of the patient's subjective symptoms, and this correlates highly with the patient's actual improvement, as acute bronchitis mainly involves subjective complaints.¹⁸ BSS will be evaluated three times, at screening, day 0 and day 7. The change in BSS between day 0 and day 7 will be the primary outcome of this trial.

Secondary outcomes

Acute bronchitis predominantly depends on subjective tools, but more reliable data can be derived if appropriate objective variables are used together. Symptom and quality of life (QOL) questionnaires will be used as subjective tools, whereas cough frequency will be used as an objective tool; among outcome measures of cough symptoms, only cough frequency and quality of life questionnaires have been shown to be valid.¹⁹

Questionnaire of Clinical Symptoms of Cough and Sputum

The Questionnaire of Clinical Symptoms of Cough and Sputum was proposed as a primary outcome measure in the Traditional Korean Medicine Clinical Practice Guidelines for Antitussives and Expectorants and was developed by remodelling the Clinical Asthma Measurement Scale in Oriental Medicine-V for cough and sputum.²⁰ It is also appropriate for preparing clinical trials of GHX02 as an IND(Investigational New Drug), as it is the suggested tool in Clinical Practice Guidelines from the Ministry of Food and Drug Safety in Korea. Questionnaire items are as follows: (1) cough –frequency, intensity, sensitivity; (2) sputum –frequency, volume, difficulty to cough-up, appearance, colour; (3) activities of daily living; (4) night-time sleeping. Each item is scored on a 4-point-scale, with a total maximum score of 40 points. This questionnaire can evaluate symptoms of cough and sputum more specifically and in more detail than the BSS.

Leicester Cough Questionnaire

The Leicester Cough Questionnaire (LCQ-K-acute) evaluates quality of life associated with cough. It consists of 19 items divided into three parts, physical, psychological, and social, each scored from 1 to 7. The total score is the sum of the average scores(1–7 points) for each part. The higher the score, the better the quality of life. Although it was initially developed as an assessment tool for chronic cough, it has also been found to be useful for acute cough, by changing the time criteria from 2 weeks to 24 hours.²¹ In addition, the validity and reliability of the Korean version of the LCQ(LCQ-K) has already been verified.²²

Frequency of coughing fits

Coughing frequency is an objective measurement tool for evaluating coughing. In this trial, we will ask participants to record how often they cough each day. A cough diary will be given to record their everyday coughing frequency, and participants will be classified into one of the following scales: 0 = 0 time/day, 1 = 1time/day, 2 = 2-3 times/day, 3 = 4-5 times/day(sometimes), 4 = 6-10 times/day(frequent), 5 = over 15 times/day(consistently).²³

Integrative Medicine Outcome Scale and Integrative Medicine Patient Satisfaction Scale

The Integrative Medicine Outcome Scale is a 5-point-scale for evaluating improvement after treatment (where, 1=complete recovery, 2=major improvement, 3=slight-to-moderate improvement, 4=no change, 5=deterioration), either by the patient or investigator (the investigator in this trial). The Integrative Medicine Patient Satisfaction Scale is a 5-point-scale for evaluating patient satisfaction with the treatment (where, 1=very satisfied, 2=satisfied, 3=neutral, 4=dissatisfied, 5=very dissatisfied).¹⁵ Both will be measured at the patients' final visit (day7). As many other clinical trials of acute bronchitis use these tools to measure overall improvement and satisfaction, using them will enable us to make direct comparisons with other medicines.

Safety assessment

Safety will be assessed in terms of adverse events (AEs), vital signs, and laboratory examinations (liver function test and routine blood and urine tests). AEs and vital signs will be recorded on a CRF at every visit, and laboratory examinations will be conducted before and after taking the medication. AEs will be defined as every unexpected sign or symptom during the trial period. All information about AEs will be recorded in detail, such as the duration and extent of the AE, relationship with the trial medicine, name of the suspected drug, etc. Common adverse events may include gastrointestinal side-effects, such as anorexia, stomach discomfort, nausea, and diarrhoea, which are not expected to be severe. However, if serious AEs occur that may lead to death or require extended hospitalization, the patient will be removed from the clinical trial as soon as possible and proper treatment will be provided (Table 2).

Data management and monitoring

The investigators will follow the Standard Operating Procedures (SOP) of the trial for a better quality of assessment and collection of outcome data. The investigators should be restricted to only physicians who have attended training meetings and can evaluate outcome measures, except for questionnaires. All assessment data and case reports will be collected at baseline (day 0) and at the end of the trial (day 7) in both the intervention and control groups. Collected documents and data will be managed by electronic CRF and encrypted using double data entry. Only the

1
2
3
4 principle investigator, or those who have permission, will be able to access the data. The original
5 paper versions of the CRFs and other documents will be stored at a separate and secure location
6 for 10 years after trial completion.
7
8

9 Multicentre clinical trial monitoring will be conducted via regular visits (every one-fourth of
10 recruitment) and occasional telephone calls. The information collected will be reported to the data
11 monitoring committee (DMC), comprising specialists in pulmonology and medical statistics who
12 are unrelated to the trial. At visits, a monitor will confirm whether the trial is being conducted in
13 accordance with the protocol and AEs are being properly reported and recorded on CRFs. The
14 monitor will check the whole progress of the clinical trial and problems will be discussed with the
15 investigator as and when they occur.
16
17
18
19
20
21
22

23 **Statistical analysis**

24
25 Data analysis will be performed by an independent statistician using SAS[®] Analytics Pro. Efficacy
26 evaluation will be based on intention-to-treat (ITT) analysis, according to PP analysis. ITT analysis
27 will be conducted for all randomized participants who took the trial medicine at least once, and
28 PP analysis will be conducted for those who completed the entire trial without violating the
29 protocol. To handle missing values when processing ITT analysis, the last-observation-carried-
30 forward (LOCF) method and multiple imputation will be used. For primary outcome analysis, the
31 change in BSS between day0 and day7 will be evaluated using analysis of covariance. Significance
32 will be accepted at a two-sided α -level of 0.05. For continuous variables, 95% confidence intervals
33 (CIs) will be calculated. Analyses of secondary outcomes will follow the same methods.
34
35
36
37
38
39

40 Safety assessment will be performed by ITT analysis; all participants will be included. Comparison
41 between the number of adverse events associated with intervention and the control treatments
42 will be performed using Kruskal-Wallis tests. Demographic and baseline data will be analysed
43 using independent two-sample *t*-tests for continuous variables, and Pearson's chi-squared or
44 Fisher's exact tests for categorical variables.
45
46
47
48
49
50

51 **ETHICS AND DISSEMINATION**

1
2
3
4 The trial protocol (version 1.0) has been approved by the Institutional Review Board (IRB) of the
5 Dunsan Korean Medicine Hospital, Daejeon University. (No. DJDSKH-17-DR-14) If the protocol
6 needs modifications, the investigators are required to inform the IRB (as well as participants) and
7 receive re-approval. Before the trial, investigators are required to provide all information related to
8 the clinical trial, including the possible benefits and risks, other therapeutic choices, and right to
9 withdraw, via a written consent form approved by the IRB. After being provided with sufficient
10 time and opportunity to ask questions and decide whether to participate, all participants are
11 required to provide written consent before study inclusion. All patient identifiable data will be
12 kept confidential, even when the results of the trial are published and participant information will
13 be stored in a secure file, and only the primary investigator (including those who have permission)
14 and the monitor will have access to the data. To ensure confidentiality, all clinical trial documents,
15 such as CRFs, will be recorded and distinguished by the participant identification number
16 throughout the trial. At the end of the trial, the study results will be disseminated via peer-
17 reviewed journals, conference presentation and the Clinical Research Information Service; the
18 participants will also be informed of the results, even unpublished data, including missing data.
19
20
21
22
23
24
25
26
27
28
29

30 **DISCUSSION**

31
32
33 Despite problems associated with antibiotic abuse in public health systems and the substantial
34 economic burden associated with acute bronchitis, currently no definitive medication is
35 recommended. There are many studies exploring the efficacy of herbal medicines; a systematic
36 review concluded that there was insufficient evidence to support the use of Chinese herbs for
37 acute bronchitis because of the high risk of bias and lack of toxicological evidence.²⁴ This study is
38 a multicentre, double-blind, randomized placebo-controlled trial to evaluate the efficacy and
39 safety of two different doses of GHX02, compared with placebo, for acute bronchitis, and we
40 followed strict quality control methods. To ensure a well-designed trial, we conducted a systemic
41 review of randomized controlled trials for acute bronchitis in the last 10 years.²⁵
42
43
44
45
46
47

48 There are some strengths and limitations to this protocol. Contrary to other trials, we will use the
49 Korean Standard Tool of Pattern Identifications of Cough and Sputum, which is a Korean Medical
50 Diagnostic Standard for categorizing cases, to obtain additional information as to whether a
51 certain categories of patients respond better than others to treatment. In this way, we will be able
52
53
54

1
2
3
4 to investigate the efficacy of GHX02 for a more specific groups of people suffering from acute
5 bronchitis. Another strength is that the outcome measures we will use in this trial is well balanced
6 between patients' subjective and objective outcomes; thus, the effectiveness of GHX02 will be
7 demonstrated from various aspects. As GHX02 is an herbal prescription which has already been
8 used for acute bronchitis, there is little risk of side-effects and the efficacy of GHX02 is already
9 proven by empirical evidence. This study will provide new evidence for the efficacy and safety of
10 GHX02 in a standard research design and is expected to be presented as a recommended
11 alternative medicine for acute bronchitis.
12
13
14
15

16
17 A limitation of this trial protocol is that we will only target adults, despite most acute bronchitis
18 patients being children under 5 years. As clinical drug trials are recommended to be first applied
19 to adults, we selected adults aged between 17 and 75 years. Further studies among children will
20 need to be conducted after completion of this study.
21
22
23
24
25

26 **Author affiliations**

27 1 Division of Respiratory System, Dept. of Internal Medicine, College of Korean Medicine, Daejeon University
28 2 East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University
29 3 Institute of Traditional Medicine and Bioscience, Daejeon University
30 4 Dept. of Applicative Statistics, College of Economics, Daejeon University
31 5 Dept. of Neuropsychology, College of Korean Medicine, Daejeon University
32
33
34

35 **Acknowledgements**

36 The authors thank the staff and patients participating in the study. Additionally, the authors thank the staff at
37 Daejeon University Dunsan Korean Medicine Hospital Clinical Trial Center (DCTC), especially Da Yeong Lee for
38 overview of the research. We also thank Ju Ah Lee for writing and drawing up the protocol.
39
40

41 **Contributors**

42 YRL drafted the research protocol and wrote the manuscript. WKY, SJP, SHK were involved in the protocol
43 development. WK contributed to the statistical design and analysis. ICJ and YCP supervised this protocol. All
44 authors contributed to the conception and implementation of this clinical trial.
45
46

47 **Funding**

48 This research was supported by the National Research Foundation of Korea Grant funded by the
49 Korean Government (NRF-2015R1D1A1A01058852), the Korea Health Technology R&D Project, Ministry of
50 Health & Welfare, Republic of Korea (grant number: HI15C0006), and Korea Institute of Oriental Medicine
51 (grant number: K17513).
52
53
54

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Competing interests

None declared.

Ethics approval

The protocol was approved by the Institutional Review Board of Dunsan Korean Medicine Hospital, Daejeon University.

Provenance and peer review

Not commissioned; externally peer reviewed.

For peer review only


REFERENCES

1. Wenzel RP, Fowler III AA. Acute bronchitis. *New England journal of medicine* 2006;355(20):2125-30.
2. Park MJ, Rhee CK, Kim YH, et al. Efficacy and safety of HL301 in the treatment of acute bronchitis and acute exacerbation of chronic bronchitis: a phase 2, randomized, double-blind, placebo-controlled, multicenter study. *Current Medical Research and Opinion* 2017;33(5):919-25.
3. Kamin W, Ilyenko LI, Malek FA, et al. Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents. *Pediatrics International* 2012;54(2):219-26.
4. Tackett KL, Atkins A. Evidence-based acute bronchitis therapy. *Journal of pharmacy practice* 2012;25(6):586-90.
5. Kinkade S, Long NA. Acute Bronchitis. *American family physician* 2016;94(7)
6. Albert RH. Diagnosis and treatment of acute bronchitis. *American family physician* 2010;82(11)
7. Steinman MA, Sauaia A, Maselli JH, et al. Office evaluation and treatment of elderly patients with acute bronchitis. *Journal of the American Geriatrics Society* 2004;52(6):875-79.
8. Smith SM, Smucny J, Fahey T. Antibiotics for acute bronchitis. *Jama* 2014;312(24):2678-79.
9. Braman SS. Chronic cough due to acute bronchitis: ACCP evidence-based clinical practice guidelines. *CHEST Journal* 2006;129(1_suppl):95S-103S.
10. Smith SM, Schroeder K, Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings. *Cochrane Database Syst Rev* 2012;8(8)
11. Cayley Jr WE. Beta2 Agonists for Acute Cough or a Clinical Diagnosis of Acute Bronchitis. *American family physician* 2017;95(9):551.
12. Timmer A, Günther J, Motschall E, et al. Pelargonium sidoides extract for treating acute respiratory tract infections. *The Cochrane Library* 2013
13. Holzinger F, Chenot J-F. Systematic review of clinical trials assessing the effectiveness of ivy leaf (*hedera helix*) for acute upper respiratory tract infections. *Evidence-Based Complementary and Alternative Medicine* 2010;2011
14. Castro M. Placebo versus best-available-therapy control group in clinical trials for pharmacologic therapies: which is better? *Proceedings of the American Thoracic Society* 2007;4(7):570-73.
15. Moher D, Chan AW. SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials). *Guidelines for Reporting Health Research: A User's Manual* 2014:56-67.
16. Gagnier JJ, Boon H, Rochon P, et al. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. *Annals of internal medicine* 2006;144(5):364-67.
17. Matthys H, Kamin W. Positioning of the Bronchitis Severity Score (BSS) for standardised use in

- clinical studies. *Current medical research and opinion* 2013;29(10):1383-90.
18. Lehl S, Matthys H, Kamin W, et al. The BSS—a valid clinical instrument to measure the severity of acute bronchitis. *Pulm Respir Res* 2014;1:00016.
19. Leconte S, Ferrant D, Dory V, et al. Validated methods of cough assessment: a systematic review of the literature. *Respiration* 2011;81(2):161-74.
20. Jang SY. the Traditional Korean Medicine Clinical Practice Guidelines for Antitussives and Expectorants. Korea Food & Drug Administration 2007:5-15.
21. Yousaf N, Lee KK, Jayaraman B, et al. The assessment of quality of life in acute cough with the Leicester Cough Questionnaire (LCQ-acute). *Cough* 2011;7(1):4.
22. Han JM, Jung IC, Kang WC, et al. Reliability and validity of leicester cough questionnaire Korean version. *Chronic respiratory disease* 2014;11(3):147-52.
23. Fischer J, Dethlefsen U. Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial. *Cough* 2013;9(1):25.
24. Jiang L, Li K, Wu T. Chinese medicinal herbs for acute bronchitis. *The Cochrane Library* 2012
25. Lyu YR, Lee EJ, Jeon JH, et al. A Systemic Review of Clinical Trials Using Medication for Acute Bronchitis: A Pre-study on the Development of Traditional Korean Medicine Clinical Practice Guideline. *Journal of Korean Medicine* 2017;38(1):93-111.

FIGURE LEGENDS

Figure 1. Flowchart of the study procedure



17-019897 on 14 May 2024. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>
Figure 1. Flowchart of the study procedure

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___p.1___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ p.12-13___
	2b	All items from the World Health Organization Trial Registration Data Set	___ p.1___
Protocol version	3	Date and version identifier	___p.12___
Funding	4	Sources and types of financial, material, and other support	___ p.14___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___ p.14___
	5b	Name and contact information for the trial sponsor	___ p.14___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___ p.14___
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	___p.11-12___

Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	___p.3-4___
	6b	Explanation for choice of comparators	___p.4___
Objectives	7	Specific objectives or hypotheses	___p.4___
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	___p.4-5___

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	___ p.4-5 ___
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	___ p.7-8___
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	___p.6___
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	___p.9, 11___
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	___p.6, 11___
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	___p.7-8___
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	___p.9-11___
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	___p.4-6___

1				
2				
3	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	___p.6___
4				
5	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	___p.7___
6				
7				

8 **Methods: Assignment of interventions (for controlled trials)**

9 Allocation:

10				
11				
12	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	___p.8___
13				
14				
15				
16				
17	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	___p.8___
18				
19				
20				
21	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	___p.8___
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	___p.8-9___
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	___p.8-9___
28				
29				
30				

31 **Methods: Data collection, management, and analysis**

32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	___p.11-12___
34				
35				
36				
37				
38		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	___p.11___
39				
40				
41				
42				
43				
44				

1				
2				
3	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	___p.11-12___
4				
5				
6				
7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	___ p.12 ___
8				
9				
10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___p.12_ ___
11				
12		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	___p.12___
13				
14				

15 **Methods: Monitoring**

16				
17	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	___p.12___
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	___p.12___
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	___p.11-12___
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	___p.12___
29				
30				
31				

32 **Ethics and dissemination**

33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	___p.12-13___
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	___p.12-13___
38				
39				
40				
41				
42				

1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	_____p.13_____
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	_____p.13_____
7				
8	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	_____p.13_____
9				
10				
11	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	_____p.13_____
12				
13				
14	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	_____p.13_____
15				
16				
17	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	_____p.13_____
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	_____ p.13_____
21				
22				
23				
24				
25		31b	Authorship eligibility guidelines and any intended use of professional writers	_____ p.13_____
26				
27		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	_____p.13_____
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	_____p.12_____
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	_____p.10-11_____
35				
36				

37 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.
 40

BMJ Open

Efficacy and safety of GHX02 in the treatment of acute bronchitis: protocol of a phase 2, double-blind, randomized placebo-controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019897.R1
Article Type:	Protocol
Date Submitted by the Author:	21-Dec-2017
Complete List of Authors:	Lyu, Yee Ran; College of Korean Medicine, Daejeon University, Division of Respiratory System, Dept. of Internal Medicine Yang, Won-Kyung ; Institute of Traditional Medicine and Bioscience, Daejeon University Park, So Jung ; Dunsan Korean Medicine Hospital of Daejeon University, East West Cancer Center Kim, Seung-Hyeong; Institute of Traditional Medicine and Bioscience, Daejeon University Kang, Wee-Chang; College of Economics, Daejeon University, Dept. of Applicative Statistics Jung, In Chul; College of Korean Medicine, Daejeon University, Dept. of Neuropsychology Park, Yang Chun; College of Korean Medicine, Daejeon University, Division of Respiratory System, Dept. of Internal Medicine
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Respiratory medicine
Keywords:	acute bronchitis, Herbal medicine < THERAPEUTICS, GHX02, randomized controlled trial

SCHOLARONE™
Manuscripts

1
2
3
4 **Efficacy and safety of GHX02 in the treatment of acute bronchitis:**
5
6 **protocol of a phase 2, double-blind, randomized placebo-**
7 **controlled trial**
8
9

10
11
12
13 Yee Ran Lyu¹, Won-Kyung Yang^{1,3}, So Jung Park², Seung-Hyung Kim³,
14 Weechang Kang⁴, In Chul Jung⁵, Yang Chun Park^{1*}
15

16
17
18 ¹ Division of Respiratory System, Dept. of Internal Medicine, College of Korean Medicine, Daejeon
19 University
20

21 ² East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University
22

23 ³ Institute of Traditional Medicine and Bioscience, Daejeon University
24

25 ⁴ Dept. of Applicative Statistics, College of Economics, Daejeon University
26

27 ⁵ Dept. of Neuropsychology, College of Korean Medicine, Daejeon University
28

29 **Correspondence to**

30 Professor Yang-Chun Park, omdpyc@dju.kr

31 Korean Internal Medicine and Director of the Clinical Trial Center

32 Dunsan Korean Medicine Hospital of Daejeon University

33 75, Daedeok-daero 176-beongil, Seo-gu, Daejeon, Republic of Korea 35235

34 Tel: 82-42-470-9126 (clinic), 82-42-229-6763 (office, Munchang Campus)

35 Fax: 82-42-470-9486
36
37
38
39
40

41 Word count : 3833
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Acute bronchitis is a self-limiting infection of the large airways; cough is the primary symptom, usually lasting for about 3 weeks. Annually, approximately 5% of adults develop acute bronchitis, and its economic burden is substantial. There are also problems of antibiotic abuse in public health systems and symptomatic therapies are commonly prescribed, for which there is insufficient supporting evidence. GHX02 contains four herbs originating from *gwaruhaengryeon-hwan*, which has been used in the treatment of acute bronchitis patients in Korea. The objective is to compare the GHX02 and placebo in terms of efficacy and safety, and to determine the appropriate dosage.

Methods and analysis: We planned a phase 2, multicentre, dose-finding, double-blind, randomized placebo-controlled trial of two different doses of GHX02 compared with placebo. A total of 150 patients, aged 19-75 years, with a Bronchitis Severity Score (BSS) ≥ 5 due to acute bronchitis starting within 2 weeks of study enrolment will be recruited from three university-affiliated hospitals across Korea. Participants will be randomly assigned to either a high-dose GHX02 group (1,920mg/day), a standard-dose GHX02 group (960mg/day), or a placebo group according to a 1:1:1 allocation ratio using stratification block randomization with pattern identification. Patients will take medications three times daily for 7 days, with 2 visiting days. The primary outcome measure is a change in BSS from day 0 to day 7. The secondary outcomes are the Questionnaire of Clinical Symptoms of Cough and Sputum, Leicester Cough Questionnaire, frequency of coughing fits, Integrative Medicine Outcome Scale, Integrative Medicine Patient Satisfaction Scale and withdrawal rate of patients with exacerbation. Safety will be assessed by adverse events, vital signs, and laboratory examinations.

Ethics and dissemination: The study has been approved by our Institutional Review Board (No. DJDSKH-17-DR-14). The trial results will be disseminated via peer-reviewed journals and the Clinical Research Information Service.

Trial registration number: NCT03310385

KEY WORDS: acute bronchitis, herbal medicine, GHX02, randomized controlled trial

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This study will provide new evidence for the efficacy and safety of GHX02 in a standard research design

- We will use the Korean Standard Tool of Pattern Identifications of Cough and Sputum, via stratified block randomization
- This is a well-designed study and the outcome measures are well balanced between patients' subjective and objective outcomes
- Limitation is that this trial protocol only targets adults
- The trial period is brief to check the complete recovery from the disease

INTRODUCTION

Acute bronchitis is the most common disease seen in outpatient departments (OPDs) across South Korea; about 5% of the general population have acute bronchitis.¹ In 2016, the Health Insurance Review & Assessment Service of South Korea estimated that more than 1500 million people visited OPDs for acute bronchitis and that the rate of increase in medical expenses, compared to that over the previous year, also rose.² Thus, acute bronchitis represents a substantial economic burden on the public health system, and effective therapeutic agents are urgently required.³

Acute bronchitis is a self-limiting infection of the large airways, with cough as the primary symptom, usually lasting for about 3 weeks.⁴ It is characterized by acute onset of cough, accompanied by the production of sputum and dyspnea or chest discomfort.⁵ As there are no specific diagnostic criteria for acute bronchitis, diagnosis is primarily clinical and requires a thorough assessment to differentiate from pneumonia, common cold, and asthma.⁶ Up to 90% of acute bronchitis is caused by viruses; bacterial infection accounts only for less than 10%. Nevertheless, 60–80% of patients, despite evidence of little or no benefit, are treated with antibiotics, contributing to bacterial resistance associated with multiple adverse effects.⁷ Several guidelines and meta-analyses of randomized controlled trials (RCTs) have concluded that antibiotic treatment is mostly ineffective in acute bronchitis, unless the infection is of bacterial origin.⁸

As antibiotics are generally not recommended for acute bronchitis, symptomatic therapy such as antitussives, expectorants, beta-2 agonists, and alternative therapies are commonly prescribed, despite insufficient evidence to support such treatments. There have been the lack of consistent evidence for their use of antitussives on acute bronchitis,⁹ and the evidence regarding the use of expectorants is also questionable.¹⁰ Beta-2 agonists are reported to be effective for patients with airflow obstruction, but adverse events like tremor and nervousness are widely observed.¹¹ Moreover, the Cochrane Reviews suggested a lack of evidence to recommend the use of Chinese

herbs in the treatment of acute bronchitis¹² and other alternative therapies, like *Pelargonium sidodes* or ivy leaf extracts are used in various European countries, with variable results.^{13 14}

Thus, there have been substantial efforts worldwide to develop effective therapeutic agents for treating acute bronchitis. In this study, we focused on herbal medicines that have been used for centuries in Oriental countries; we sought to evaluate the efficacy and safety of GHX02, which contains four herbs originating from *gwaruhaengryeon-hwan* (GRHRH) in Donguibogam (Principles and Practice of Eastern Medicine) (Table1). GHX02 has been used for the treatment of patients with acute bronchitis in the Dunsan Korean Medicine Hospital, Daejeon University, and its effectiveness against acute cough has already been demonstrated. We planned a phase 2, multicentre, dose-finding, double-blind, randomized placebo-controlled trial of two different doses of GHX02 compared with placebo. The objective is to compare the GHX02 and placebo in terms of efficacy and safety, and to determine the appropriate dosage of GHX02 required for the treatment of acute bronchitis. We chose a placebo as the control, as this is the most rigorous test for evaluating the efficacy of new medical therapy in a double-blind RCT.¹⁵ In addition, as acute bronchitis is a self-limiting disorder, placebo control is ethically justifiable.

Table1. Components of GHX02

Herb	Latin name	Family name	Part of plant	Amount
Gwaruin	<i>Trichosanthis Semen</i>	Cucurbitaceae	Seed	351mg
Haengin	<i>Armeniacaee Semen</i>	Rosaceae	Seed	175.5mg
Hwangryeon	<i>Coptidis Rhizoma</i>	Ranunculaceae	Root stock	175.5mg
Hwangkeum	<i>Scutellariae Radix</i>	Labiatae/Lamiacea	Root	351mg

METHODS AND ANALYSIS

Trial Design

This study is a phase 2, multicentre, dose-finding, double-blind, randomized placebo-controlled trial to evaluate the efficacy and safety of two different doses of GHX02, compared with placebo, for acute bronchitis. The trial will be conducted at three university-affiliated hospitals, including the Dunsan Korean Medicine Hospital, Daejeon University; the Kyunghee University Korean

Medicine Hospital; and the Pusan National University Korean Medicine Hospital. One-hundred and fifty patients will be included in this trial and randomly assigned to either a high-dose GHX02 group (1920mg/day), standard-dose GHX02 group (960mg/day), or control group (placebo) in a 1:1:1 allocation ratio. Patients will take one of the medications three times a day for 7 days, with 2 visiting days (day0, day7). On the screening day, we will use the Korean Standard Tool of Pattern Identification of Cough and Sputum, a diagnostic criterion that determines therapy in Traditional Korean Medicine, to allocate patients into three groups of *wind-heat*, *wind-cold* or *others* (Figure1, Table2). This follows the guidelines of the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)¹⁶, Reporting Randomized, Controlled Trials of Herbal Interventions¹⁷ and the trial will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and Consolidated Standards of Reporting Trials (CONSORT) guidelines.¹⁸

Table2. Timetable of study period

TIMEPOINT	STUDY PERIOD			
	Enrolment screening	Allocation Day 0	Post-allocation Day 0 Day 7	
ENROLMENT:				
Eligibility screen	X			
Informed consent	X			
Demographic data	X			
Vital signs	X		X	X
Past history	X			
Concomitant medication	X		X	X
Physical examination & radiography	X			
Laboratory examination	X			X
Pattern identification of cough & sputum	X			
Allocation		X		
INTERVENTIONS:				
High-dose GHX02			←————→	
Standard-dose GHX02			←————→	
Placebo			←————→	
ASSESSMENTS:				
BSS	X		X	X
QCSCS			X	X
LCQ-K-acute			X	X
Frequency of cough fits			←————→	
IMOS, IMPSS				X

Withdrawal rate of patients with exacerbation				X
Concomitant therapy			X	X
Adverse events			X	X
Compliance				X

BSS, Bronchitis Severity Score; QCSCS, Questionnaire on Clinical Symptoms of Cough & Sputum; LCQ-K-acute, Leicester Cough Questionnaire-Korean version-acute; IMOS, Integrative Medicine Outcome Scale; IMPSS, Integrative Medicine Patient Satisfaction Scale

Study Drug and Placebo

GHX02 is a combination of the following four herbs: Gwaruin (*Trichosanthis Semen*, 351 mg/tablet), Haengin (*Armeniacae Semen*, 175.5 mg/tablet), Hwangryeon (*Coptidis Rhizoma*, 175.5 mg/tablet), Hwangkeum (*Scutellariae Radix*, 351 mg/tablet) (Table1). One GHX02 tablet (500mg/tablet) contains 160.0mg of dry extract of the four herbs (obtained by boiling in water and then dehydrating) mixed with 340.0mg of starch and lactose. The placebo tablet does not contain any of these active ingredients but is matched in terms of colour, smell, and taste. The dosage was determined according to the Pharmacologically Active Dose (PAD) in expectorant effective tests. Both tablets are pink and round and will be provided by Hankookshinyak Corporation (Nonsan, Korea). The manufacturer complies with the provisions of the Regulations on the Safety of Pharmaceuticals and will manage the quality appropriately. Safety and toxicological tests of GHX02 will be conducted simultaneously. All allocated patients will be prescribed 4 tablets of either the clinical medicine or placebo to be administered three times daily for 7 days, and the number of remaining tablets will be recorded on day 7 to calculate compliance. To improve compliance, participants will be asked to record their daily dosage in the cough diary. The overall medication compliance during the trial should be at least 75%; if the medication compliance is less than 75%, the participant will be considered inadequate and excluded from the per-protocol (PP) analysis group.

Sample size

The estimated sample size required for this study is 150 patients (50 patients per group).¹⁹ The estimation of the number of subjects is based on whether there is a difference in the change from baseline (day 0) to post-dose (day 7) BSS, between the control and standard-dose GHX02 group.

1
2
3
4 In an earlier comparable clinical study, the difference was reported to be 2.3, and the standard
5 deviation of the changes in BSS, was estimated to be 3.2.²⁰ The power to detect the difference
6 was assumed to be 0.8, and the two-sided significance level was 0.05. The ratio of allocation of
7 subjects between the groups was 1:1:1, and dropout rate was presumed to be 0.2.
8
9

10 11 12 13 **Recruitment**

14
15
16 Participants will be recruited from the outpatient departments (OPDs) of the affiliated hospitals.
17 Recruitment will commence in January 2018.
18
19

20 21 22 **Participants**

23 Inclusion criteria

24
25
26 Potential participants who meet the following criteria will be included in this trial: (1) age 19–75
27 years; (2) BSS \geq 5 points at day 0 due to acute bronchitis; (3) symptoms starting within 2 weeks
28 before study inclusion; (4) patients who consent to participate. Diagnoses of acute bronchitis will
29 be based on patients' medical history, physical examinations, and BSS, including cough, sputum,
30 dyspnea, chest pain during coughing, and rales on auscultation.
31
32
33

34 Exclusion criteria

35
36
37 Patients with any of the following criteria will be excluded from this trial: (1) pregnant or breast-
38 feeding; (2) treatment with antibiotics, bronchodilators, glucocorticoids, immune-depressants, or
39 other clinical trial medicines during the last 4 weeks before study inclusion; (3) treatment with
40 antitussives or expectorants during the last 7 days before study inclusion; (4) history or presence
41 of confounding respiratory disease that may affect evaluation of the efficacy of clinical medicine
42 (e.g. chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, asthma,
43 pneumonia, cystic fibrosis, lung cancer, or active pulmonary tuberculosis); (5) liver or renal
44 impairment (alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline
45 phosphatase [ALP] \geq 2 times the normal upper limit, or creatinine $>$ 3.0 mg/dL at screening); (6)
46
47
48
49
50
51
52
53

1
2
3
4 history or presence of clinically relevant cardiovascular, renal, metabolic, haematological,
5 neurological, psychiatric, systemic, infectious disease, or malignant tumour (except where there is
6 no recurrence for more than 5 years after surgery); (7) genetic problems such as galactose
7 intolerance, Lapp lactose deficiency or glucose-galactose malabsorption; (8) history of alcoholism
8 or substance abuse; (9) participation in other clinical medicine trials during the last 30 days before
9 study inclusion; (10) judged by the investigators to be inappropriate for the clinical trial.
10 Additional treatment will not be permitted during the trial, and participants are recommended not
11 to alter their exercise pattern or diet. Drugs that may affect bronchitis symptoms or that have a
12 similar therapeutic purpose to the trial medication will not be permitted, including antibiotics,
13 bronchodilators, glucocorticoids, immune-depressants, antitussives, expectorants or any other
14 clinical trial medicine. Those who require or take these concomitant medicines during the trial will
15 be excluded from this study. Other medications will only be permitted at the discretion of the
16 investigators. All drug information (name of product, purpose of administration, dosage, duration
17 of administration, etc.) will be recorded on the patient case report form (CRF).
18
19
20
21
22
23
24
25
26
27
28

29 Randomization and allocation concealment

30
31 An independent statistician will conduct randomization, using a computer random number
32 generator of SAS[®] Analytics Pro (SAS Institute, Inc., Cary, North Carolina, USA). Allocation will be
33 implemented by the manufacturers who collectively label serial numbers, by generating
34 randomized numbers and handing over the sealed set to the management pharmacist. When the
35 investigator requests for medication, the management pharmacist gives the participant a test drug
36 or a placebo corresponding to the participant's identification code. We will allocate three groups
37 (*wind-heat*, *wind-cold*, or *others*) at a 1:1:1 ratio of high-dose, standard-dose, and placebo
38 treatment. Stratified block randomization using the Korean Standard Tool of Pattern Identifications
39 of Cough and Sputum will be performed in this trial.
40
41
42
43
44
45
46
47
48
49

50 *Korean Standard Tool of Pattern Identifications of Cough and Sputum*

51 The Korean Standard Tool of Pattern Identifications of Cough and Sputum is used to identify
52 patterns of acute bronchitis patients. This pattern identification is an important diagnostic criterion
53
54

1
2
3
4 in Korean medicine which is used for deciding medication and other therapies. It was proposed in
5 the Traditional Korean Medicine Clinical Practice Guidelines for Antitussives and Expectorants for
6 Korean Medical Diagnostic Standards.²¹ This comprises 56 items to classify cases into three
7 patterns: *wind-cold*, *wind-heat* or *others*. We will investigate the correlation between the patterns
8 and the efficacy of GHX02; the *wind-heat* patterns group is expected to show greater response
9 than the other groups to the therapeutic effects of GHX02.
10
11
12
13
14
15

16 **Blinding**

17
18 This is a double-blind trial, thus neither participants nor investigators (including outcome
19 assessors) will be aware of group assignment until the end of the study period. Placebo tablets
20 will be matched to GHX02 tablets in terms of colour, taste, and smell, as well as outer packaging.
21 Elimination of blindness will only be considered in cases of serious medical emergencies.
22
23
24
25
26
27

28 **Outcome measures**

29
30 Primary outcome

31 *Bronchitis Severity Score*

32
33 The BSS was developed as an evaluation tool for acute bronchitis in 1996 and was recently shown
34 to be valid and reliable by the European Medicines Agency's Committee on Herbal Medicinal
35 Products (HMPC).²⁰ It has been used successfully in many clinical trials for acute bronchitis. BSS
36 comprises the sum of five major symptom scores for acute bronchitis: cough, sputum, dyspnea,
37 chest pain during coughing, and rales on auscultation. Each symptom is scored on a 4-point-scale
38 (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe), with a maximum total score of 20
39 points. The investigator assesses symptom scores on the basis of the patient's subjective
40 symptoms, and this correlates highly with the patient's actual improvement, as acute bronchitis
41 mainly involves subjective complaints.²² The change in BSS between day 0 and day 7 will be the
42 primary outcome of this trial.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Secondary outcomes

Assessment of acute bronchitis predominantly depends on subjective tools, but more reliable data can be derived if appropriate objective variables are used together. Symptom and quality of life (QOL) questionnaires will be used as subjective tools, whereas cough frequency will be used as an objective tool; among outcome measures of cough symptoms, only cough frequency and quality of life questionnaires have been shown to be valid.²³

Questionnaire of Clinical Symptoms of Cough and Sputum

The Questionnaire of Clinical Symptoms of Cough and Sputum (QCSCS) was proposed as a primary outcome measure in the Traditional Korean Medicine Clinical Practice Guidelines for Antitussives and Expectorants²¹ and was developed by remodelling the Clinical Asthma Measurement Scale in Oriental Medicine-V for cough and sputum.²⁴ It is also appropriate for preparing clinical trials of GHX02 as an Investigational New Drug (IND), as it is the suggested tool in Clinical Practice Guidelines from the Ministry of Food and Drug Safety in Korea. Questionnaire items are as follows: (1) cough – frequency, intensity, sensitivity; (2) sputum – frequency, volume, difficulty to cough-up, appearance, colour; (3) activities of daily living; (4) night-time sleeping. Each item is scored on a 4-point-scale, with a total maximum score of 40 points. This questionnaire can evaluate symptoms of cough and sputum more specifically and in more detail than the BSS. The changes in QCSCS from day0 to day7 will be analysed for a secondary outcome.

Leicester Cough Questionnaire

The Leicester Cough Questionnaire (LCQ-K-acute) evaluates quality of life associated with cough. It consists of 19 items divided into three parts, physical, psychological, and social, each scored from 1 to 7. The total score is the sum of the average scores (1–7 points) for each part. The higher the score, the better the quality of life. Although it was initially developed as an assessment tool for chronic cough, it has also been found to be useful for acute cough, by changing the time criteria from 2 weeks to 24 hours.²⁵ In addition, the validity and reliability of the Korean version of the LCQ(LCQ-K) has already been verified.²⁶ The changes of LCQ-K-acute between day0 and day7 will be evaluated.

Frequency of coughing fits

Coughing frequency is an objective measurement tool for evaluating coughing. In this trial, we will ask participants to record how often they cough each day. A cough diary will be given to record their everyday coughing frequency, and participants will be classified into one of the following scales: 0 = 0 time/day, 1 = 1 time/day, 2 = 2-3 times/day, 3 = 4-5 times/day(sometimes), 4 = 6-10 times/day(frequent), 5 = over 15 times/day(consistently).²⁷ We will evaluate the frequency of coughing fits daily from day0 to day7 and analyse the changes in frequency of coughing fits after 1-7days from the baseline. (change in frequency of coughing fits after k days of study = frequency of coughing fits after k days of study - frequency of coughing fits at day0, where k = 1, 2, ..., 7)

Integrative Medicine Outcome Scale and Integrative Medicine Patient Satisfaction Scale

The Integrative Medicine Outcome Scale is a 5-point-scale for evaluating improvement after treatment (where, 1=complete recovery, 2=major improvement, 3=slight-to-moderate improvement, 4=no change, 5=deterioration), either by the patient or investigator (the investigator in this trial). The Integrative Medicine Patient Satisfaction Scale is a 5-point-scale for evaluating patient satisfaction with the treatment (where, 1=very satisfied, 2=satisfied, 3=neutral, 4=dissatisfied, 5=very dissatisfied).²⁰ Both will be measured at the patients' final visit (day7) and will be analysed for a secondary outcome.

Withdrawal rate of patients with exacerbation

Exacerbation in this trial means progression of acute bronchitis to bacterial bronchitis or pneumonia, requiring concomitant medicine such as antibiotics, bronchodilators, glucocorticoids, etc. During the trial, patients will be asked to inform about any signs of worsening symptoms, and investigators will evaluate appropriate measures if they need additional therapy. Those who require concomitant medicines will be excluded from the trial and provided the necessary medicine. We will calculate this withdrawal rate in each intervention and control group to check

1
2
3
4 the relevance with drug effects.
5
6
7

8 **Safety assessment** 9

10 Safety will be assessed in terms of adverse events (AEs), vital signs, and laboratory examinations
11 (liver function test and routine blood and urine tests). AEs and vital signs will be recorded on a
12 CRF at every visit, and laboratory examinations will be conducted before and after taking the
13 medication. AEs are defined as every unexpected sign or symptom during the trial period and
14 participants are asked to inform about any of these AEs during medication. All information about
15 AEs will be recorded in detail, such as the duration and extent of the AE, relationship with the trial
16 medicine, name of the suspected drug, etc. Common adverse events may include gastrointestinal
17 side-effects, such as anorexia, stomach discomfort, nausea, and diarrhoea, which are not expected
18 to be severe. However, if serious AEs occur that may lead to death or require extended
19 hospitalization, the patient will be removed from the clinical trial as soon as possible and proper
20 treatment will be provided (Table2).
21
22
23
24
25
26
27
28
29
30

31 **Data management and monitoring** 32

33 The investigators will follow the Standard Operating Procedures (SOP) of the trial for a better
34 quality of assessment and collection of outcome data. The investigators who evaluate outcome
35 measures should be restricted to only physicians who have attended the training meetings. All
36 assessment data and case reports will be collected at baseline (day0) and at the end of the trial
37 (day7) in both the intervention and control groups. Collected documents and data will be
38 managed by electronic CRF and encrypted using double data entry. Only the principle investigator,
39 or those who have permission, will be able to access the data. The CRFs and other documents will
40 be stored at a separate and secure location for 10 years after trial completion.
41
42
43
44
45
46

47 Multicentre clinical trial monitoring will be conducted via regular visits (every one-fourth of
48 recruitment) and occasional telephone calls. The information collected will be reported to the data
49 monitoring committee (DMC), comprising specialists in pulmonology and medical statistics who
50 are unrelated to this trial. At visits, a monitor will confirm whether the trial is being conducted in
51 accordance with the protocol and especially AEs are being properly reported and recorded on
52
53
54

1
2
3
4 CRFs. The monitor will check the whole process of the clinical trial and problems will be discussed
5 with the investigator as and when they occur.
6
7
8
9

10 **Statistical analysis**

11
12 Data analysis will be performed by an independent statistician using SAS[®] Analytics Pro.
13 Continuous variables will be summarized by Mean±SD, and categorical variables will be reported
14 with frequencies and percentages according to three treatment groups. Efficacy evaluation will be
15 primarily based on the intention-to-treat (ITT) analysis, and per-protocol (PP) analysis will be used
16 as a secondary analysis. ITT analysis will be conducted for all subjects randomized, and PP analysis
17 will be conducted for those who completed the entire trial without violating the protocol. For
18 primary outcome analysis, the changes in BSS between day0 and day7 will be evaluated using
19 analysis of covariance (ANCOVA) which contains the day0's BSS and the treatment group as
20 covariates. Significance will be accepted at a two-sided test with α -level of 0.05. For effects of
21 GHX02 treatments compared with the control group, 95% confidence intervals (CIs) will be
22 calculated. Analyses of secondary outcomes will be carried out as follows: QCSCS and LCQ-K-
23 acute by ANCOVA including its baseline value respectively; frequency of coughing fits by linear
24 mixed models (LMMs); IMOS and IMPSS by analysis of variance (ANOVA); and withdrawal rate of
25 patients with exacerbation by Pearson's chi-squared or Fisher's exact tests. To handle missing
26 values when processing ITT analysis, the last-observation-carried-forward (LOCF) method will be
27 used except for frequency of coughing fits analysed with LMMs in which missing values need not
28 to be imputed.
29
30
31
32
33
34
35
36
37
38
39

40 Safety assessment will be performed by ITT analysis; all participants randomized will be included.
41 Comparison of the number of adverse events between three treatment groups will be performed
42 using Kruskal-Wallis tests. Demographic and baseline data will be analysed using ANOVA for
43 continuous variables, and Pearson's chi-squared or Fisher's exact tests for categorical variables.
44
45
46
47
48

49 **ETHICS AND DISSEMINATION**

50
51 The trial protocol (version 1.0) has been approved by the Institutional Review Board (IRB) of the
52 Dunsan Korean Medicine Hospital, Daejeon University (No. DJDSKH-17-DR-14) and has been
53
54

1
2
3
4 registered through the clinical trials registry (NCT03310385). If the protocol needs modifications,
5 the investigators are required to inform the IRB (as well as participants) and receive re-approval.
6 Before the trial, investigators are required to provide all information related to the clinical trial,
7 including the possible benefits and risks, other therapeutic choices, and right to withdraw, via a
8 written consent form approved by the IRB. After being provided with sufficient time and
9 opportunity to ask questions and decide whether to participate, all participants are required to
10 provide written consent before study inclusion. All patient identifiable data will be kept
11 confidential, even when the results of the trial are published and participant information will be
12 stored in a secure file, and only the primary investigator (including those who have permission)
13 and the monitor will have access to the data. To ensure confidentiality, all clinical trial documents,
14 such as CRFs, will be recorded and distinguished by the participant identification number
15 throughout the trial. At the end of the trial, the study results will be disseminated via peer-
16 reviewed journals, conference presentation and the Clinical Research Information Service; the
17 participants will also be informed of the results, even unpublished data, including missing data.
18
19
20
21
22
23
24
25
26
27
28

29 DISCUSSION

30
31 Despite problems associated with antibiotic abuse in public health systems and the substantial
32 economic burden associated with acute bronchitis, currently no definitive medication is
33 recommended. There are many studies exploring the efficacy of herbal medicines; a systematic
34 review concluded that there was insufficient evidence to support the use of Chinese herbs for
35 acute bronchitis because of the high risk of bias and lack of toxicological evidence.¹² This study is
36 a multicentre, double-blind, randomized placebo-controlled trial to evaluate the efficacy and
37 safety of two different doses of GHX02, compared with placebo, for acute bronchitis, and we
38 followed strict quality control methods. To ensure a well-designed trial, we conducted a systematic
39 review of randomized controlled trials for acute bronchitis in the last 10 years.²⁸
40
41
42
43
44
45

46 There are some strengths and limitations to this protocol. Contrary to other trials, we will use the
47 Korean Standard Tool of Pattern Identifications of Cough and Sputum, which is a Korean Medical
48 Diagnostic Standard for categorizing cases, to obtain additional information as to whether a
49 certain categories of patients respond better than others to treatment. In this way, we will be able
50 to investigate the efficacy of GHX02 for more specific categories of people suffering from acute
51
52
53
54

1
2
3
4 bronchitis. Another strength is that the outcome measures we will use in this trial is well balanced
5 between patients' subjective and objective outcomes; thus, the effectiveness of GHX02 will be
6 demonstrated from various aspects. As GHX02 is an herbal prescription which has already been
7 used for acute bronchitis, there is little risk of side-effects and the efficacy of GHX02 is already
8 proven by empirical evidence. This study will provide new evidence for the efficacy and safety of
9 GHX02 in a standard research design and is expected to be presented as a recommended
10 alternative medicine for acute bronchitis.
11
12
13
14

15
16 A limitation of this trial protocol is that we will only target adults, despite most acute bronchitis
17 patients being children under 5 years. As clinical drug trials are recommended to be first applied
18 to adults, we selected adults aged between 19 and 75 years. Further studies for children will need
19 to be conducted after completion of this study.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Author affiliations

1 Division of Respiratory System, Dept. of Internal Medicine, College of Korean Medicine, Daejeon University

2 East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University

3 Institute of Traditional Medicine and Bioscience, Daejeon University

4 Dept. of Applicative Statistics, College of Economics, Daejeon University

5 Dept. of Neuropsychology, College of Korean Medicine, Daejeon University

Acknowledgements

The authors thank the staff and patients participating in the study. Additionally, the authors thank the staff at Daejeon University Dunsan Korean Medicine Hospital Clinical Trial Center (DCTC), especially Da Yeong Lee for overview of the research. We also thank Ju Ah Lee for writing and drawing up the protocol.

Contributors

YRL drafted the research protocol and wrote the manuscript. WKY, SJP, SHK were involved in the protocol development. WK contributed to the statistical design and analysis. ICJ and YCP supervised this protocol. All authors contributed to the conception and implementation of this clinical trial.

Funding

This research was supported by the National Research Foundation of Korea Grant funded by the Korean Government (NRF-2015R1D1A1A01058852), the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (grant number: HI15C0006), and Korea Institute of Oriental Medicine (grant number: K17510).

Competing interests

None declared.

Ethics approval

The protocol was approved by the Institutional Review Board of Dunsan Korean Medicine Hospital, Daejeon University.

Provenance and peer review

Not commissioned; externally peer reviewed.

REFERENCES

1. Wenzel RP, Fowler III AA. Acute bronchitis. *New England journal of medicine* 2006;355(20):2125-30.
2. Park MJ, Rhee CK, Kim YH, et al. Efficacy and safety of HL301 in the treatment of acute bronchitis and acute exacerbation of chronic bronchitis: a phase 2, randomized, double-blind, placebo-controlled, multicenter study. *Current Medical Research and Opinion* 2017;33(5):919-25.
3. Kamin W, Ilyenko LI, Malek FA, et al. Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents. *Pediatrics International* 2012;54(2):219-26.
4. Tackett KL, Atkins A. Evidence-based acute bronchitis therapy. *Journal of pharmacy practice* 2012;25(6):586-90.
5. Kinkade S, Long NA. Acute Bronchitis. *American family physician* 2016;94(7)
6. Albert RH. Diagnosis and treatment of acute bronchitis. *American family physician* 2010;82(11)
7. Steinman MA, Sauaia A, Maselli JH, et al. Office evaluation and treatment of elderly patients with acute bronchitis. *Journal of the American Geriatrics Society* 2004;52(6):875-79.
8. Smith SM, Smucny J, Fahey T. Antibiotics for acute bronchitis. *Jama* 2014;312(24):2678-79.
9. Braman SS. Chronic cough due to acute bronchitis: ACCP evidence-based clinical practice guidelines. *CHEST Journal* 2006;129(1_suppl):95S-103S.
10. Smith SM, Schroeder K, Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings. *Cochrane Database Syst Rev* 2012;8(8)
11. Cayley Jr WE. Beta2 Agonists for Acute Cough or a Clinical Diagnosis of Acute Bronchitis. *American family physician* 2017;95(9):551.
12. Jiang L, Li K, Wu T. Chinese medicinal herbs for acute bronchitis. *The Cochrane Library* 2012
13. Timmer A, Günther J, Motschall E, et al. Pelargonium sidoides extract for treating acute respiratory tract infections. *The Cochrane Library* 2013
14. Holzinger F, Chenot J-F. Systematic review of clinical trials assessing the effectiveness of ivy leaf (*hedera helix*) for acute upper respiratory tract infections. *Evidence-Based Complementary and Alternative Medicine* 2010;2011
15. Castro M. Placebo versus best-available-therapy control group in clinical trials for pharmacologic therapies: which is better? *Proceedings of the American Thoracic Society* 2007;4(7):570-73.
16. Moher D, Chan AW. SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials). *Guidelines for Reporting Health Research: A User's Manual* 2014:56-67.
17. Cheng C-w, Wu T-x, Shang H-c, et al. CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration. *Annals of internal medicine* 2017;167(2):112-21.

18. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMC medicine* 2010;8(1):18.
19. Chow S, Shao J. Wang, Sample Size Calculations In Clinical Research: Taylor & Francis, NY, 2003.
20. Matthys H, Kamin W. Positioning of the Bronchitis Severity Score (BSS) for standardised use in clinical studies. *Current medical research and opinion* 2013;29(10):1383-90.
21. Ministry of Food and Drug Safety, Herbal medicine Evaluation Department. The Traditional Korean Medicine Clinical Practice Guidelines for Antitussives and Expectorants. Seoul: Ministry of Food and Drug Safety 2007:5-15.
22. Lehl S, Matthys H, Kamin W, et al. The BSS—a valid clinical instrument to measure the severity of acute bronchitis. *Pulm Respir Res* 2014;1:00016.
23. Leconte S, Ferrant D, Dory V, et al. Validated methods of cough assessment: a systematic review of the literature. *Respiration* 2011;81(2):161-74.
24. Baek H-j, Lee B-j, Jung S-k, et al. Retrospective Study of Patients with Cough Treated with Eunhwayeongyo-tang. *The Journal of Internal Korean Medicine* 2016;37(6):961-77.
25. Yousaf N, Lee KK, Jayaraman B, et al. The assessment of quality of life in acute cough with the Leicester Cough Questionnaire (LCQ-acute). *Cough* 2011;7(1):4.
26. Han J-M, Jung I-C, Kang W, et al. Reliability and validity of leicester cough questionnaire Korean version. *Chronic respiratory disease* 2014;11(3):147-52.
27. Fischer J, Dethlefsen U. Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial. *Cough* 2013;9(1):25.
28. Lyu Y, Lee EJ, Jeon JH, et al. A Systemic Review of Clinical Trials Using Medication for Acute Bronchitis: A Pre-study on the Development of Traditional Korean Medicine Clinical Practice Guideline. *Journal of Korean Medicine* 2017;38(1):93-111.

FIGURE LEGENDS

Figure 1. Flowchart of the study procedure




Figure1. Flowchart of the study procedure

Figure1. Flowchart of the study procedure

81x60mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___p.3___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ p.2,13___
	2b	All items from the World Health Organization Trial Registration Data Set	___p.2,5___
Protocol version	3	Date and version identifier	___p.13___
Funding	4	Sources and types of financial, material, and other support	___p.16___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___p.16___
	5b	Name and contact information for the trial sponsor	___p.16___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___p.16___
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	___p.12-13___

Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	___p.3-4___
	6b	Explanation for choice of comparators	___p.4___
Objectives	7	Specific objectives or hypotheses	___p.4___
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	___p.4-5___

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	___ p.4-5_ ___
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	___ p.7-8___
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	___p.6___
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	___p.8,9,11___
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	___p.6, 11___
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	___p.7-8___
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	___p.9-12___
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	___p.4-6___

1				
2				
3	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	___p.6-7___
4				
5	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	___p.7___
6				
7				

8 **Methods: Assignment of interventions (for controlled trials)**

9 Allocation:

10				
11				
12	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	___p.8___
13				
14				
15				
16				
17	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	___p.8___
18				
19				
20				
21	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	___p.8___
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	___p.8-9___
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	___p.8-9___
28				
29				
30				

31 **Methods: Data collection, management, and analysis**

32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	___p.12-13___
34				
35				
36				
37				
38		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	___p.12-13___
39				
40				
41				
42				
43				
44				
45				
46				
47				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	___p.11-12___
-----------------	----	---	---------------

Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	___ p.13 ___
---------------------	-----	--	--------------

20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___p.13 ___
-----	--	-------------

20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	___p.13___
-----	---	------------

Methods: Monitoring

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	___p.12___
-----------------	-----	---	------------

21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	___p.12___
-----	---	------------

Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	___p.12___
-------	----	---	------------

Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	___p.12___
----------	----	---	------------

Ethics and dissemination

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	___p.13-14___
--------------------------	----	---	---------------

Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	___p.13-14___
---------------------	----	--	---------------



1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	_____p.14_____
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	_____p.14_____
7				
8	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	_____p.14_____
9				
10				
11	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	_____p.14_____
12				
13				
14	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	_____p.14_____
15				
16				
17	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	_____p.14_____
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	_____p.14_____
21				
22				
23				
24				
25		31b	Authorship eligibility guidelines and any intended use of professional writers	_____p.14_____
26				
27		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	_____p.14_____
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	_____p.14_____
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	_____p.12_____
35				
36				

37 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.
 40

BMJ Open

Efficacy and safety of GHX02 in the treatment of acute bronchitis: protocol of a phase 2, double-blind, randomized placebo-controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019897.R2
Article Type:	Protocol
Date Submitted by the Author:	06-Feb-2018
Complete List of Authors:	Lyu, Yee Ran; College of Korean Medicine, Daejeon University, Division of Respiratory System, Dept. of Internal Medicine Yang, Won-Kyung ; Institute of Traditional Medicine and Bioscience, Daejeon University Park, So Jung ; Dunsan Korean Medicine Hospital of Daejeon University, East West Cancer Center Kim, Seung-Hyeong; Institute of Traditional Medicine and Bioscience, Daejeon University Kang, Wee-Chang; College of Economics, Daejeon University, Dept. of Applicative Statistics Jung, In Chul; College of Korean Medicine, Daejeon University, Dept. of Neuropsychology Park, Yang Chun; College of Korean Medicine, Daejeon University, Division of Respiratory System, Dept. of Internal Medicine
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Respiratory medicine
Keywords:	acute bronchitis, Herbal medicine < THERAPEUTICS, GHX02, randomized controlled trial

SCHOLARONE™
Manuscripts

1
2
3
4 **Efficacy and safety of GHX02 in the treatment of acute bronchitis:**
5
6 **protocol of a phase 2, double-blind, randomized placebo-**
7 **controlled trial**
8
9

10
11
12
13 Yee Ran Lyu¹, Won-Kyung Yang^{1,3}, So Jung Park², Seung-Hyung Kim³,
14 Weechang Kang⁴, In Chul Jung⁵, Yang Chun Park^{1*}
15

16
17
18 ¹ Division of Respiratory System, Dept. of Internal Medicine, College of Korean Medicine, Daejeon
19 University
20

21 ² East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University
22

23 ³ Institute of Traditional Medicine and Bioscience, Daejeon University
24

25 ⁴ Dept. of Applicative Statistics, College of Economics, Daejeon University
26

27 ⁵ Dept. of Neuropsychology, College of Korean Medicine, Daejeon University
28

29 **Correspondence to**

30 Professor Yang-Chun Park, omdpyc@dju.kr

31 Korean Internal Medicine and Director of the Clinical Trial Center

32 Dunsan Korean Medicine Hospital of Daejeon University

33 75, Daedeok-daero 176-beongil, Seo-gu, Daejeon, Republic of Korea 35235

34 Tel: 82-42-470-9126 (clinic), 82-42-229-6763 (office, Munchang Campus)

35 Fax: 82-42-470-9486
36
37
38
39
40

41 Word count : 3833
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Acute bronchitis is a self-limiting infection of the large airways; cough is the primary symptom, usually lasting for about 3 weeks. Annually, approximately 5% of adults develop acute bronchitis, and its economic burden is substantial. There are also problems of antibiotic abuse in public health systems and symptomatic therapies are commonly prescribed, for which there is insufficient supporting evidence. GHX02 contains four herbs originating from *gwaruhaengryeon-hwan*, which has been used in the treatment of acute bronchitis patients in Korea. The objective is to compare the GHX02 and placebo in terms of efficacy and safety, and to determine the appropriate dosage.

Methods and analysis: We planned a phase 2, multicentre, dose-finding, double-blind, randomized placebo-controlled trial of two different doses of GHX02 compared with placebo. A total of 150 patients, aged 19-75 years, with a Bronchitis Severity Score (BSS) ≥ 5 due to acute bronchitis starting within 2 weeks of study enrolment will be recruited from three university-affiliated hospitals across Korea. Participants will be randomly assigned to either a high-dose GHX02 group (1,920mg/day), a standard-dose GHX02 group (960mg/day), or a placebo group according to a 1:1:1 allocation ratio using stratification block randomization with pattern identification. Patients will take medications three times daily for 7 days, with 2 visiting days. The primary outcome measure is a change in BSS from day 0 to day 7. The secondary outcomes are the Questionnaire of Clinical Symptoms of Cough and Sputum, Leicester Cough Questionnaire, frequency of coughing fits, Integrative Medicine Outcome Scale, Integrative Medicine Patient Satisfaction Scale and withdrawal rate of patients with exacerbation. Safety will be assessed by adverse events, vital signs, and laboratory examinations.

Ethics and dissemination: The study has been approved by our Institutional Review Board (No. DJDSKH-17-DR-14). The trial results will be disseminated via peer-reviewed journals and the Clinical Research Information Service.

Trial registration number: NCT03310385

KEY WORDS: acute bronchitis, herbal medicine, GHX02, randomized controlled trial

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This study will provide new evidence for the efficacy and safety of GHX02 in a standard research design

- We will use the Korean Standard Tool of Pattern Identifications of Cough and Sputum, via stratified block randomization
- This is a well-designed study and the outcome measures are well balanced between patients' subjective and objective outcomes
- Limitation is that this trial protocol only targets adults
- This clinical trial was limited in that complete remission of acute bronchitis could not be observed due to the short trial period

INTRODUCTION

Acute bronchitis is the most common disease seen in outpatient departments (OPDs) across South Korea; about 5% of the general population have acute bronchitis.¹ In 2016, the Health Insurance Review & Assessment Service of South Korea estimated that more than 1500 million people visited OPDs for acute bronchitis and that the rate of increase in medical expenses, compared to that over the previous year, also rose.² Thus, acute bronchitis represents a substantial economic burden on the public health system, and effective therapeutic agents are urgently required.³

Acute bronchitis is a self-limiting infection of the large airways, with cough as the primary symptom, usually lasting for about 3 weeks.⁴ It is characterized by acute onset of cough, accompanied by the production of sputum and dyspnea or chest discomfort.⁵ As there are no specific diagnostic criteria for acute bronchitis, diagnosis is primarily clinical and requires a thorough assessment to differentiate from pneumonia, common cold, and asthma.⁶ Up to 90% of acute bronchitis is caused by viruses; bacterial infection accounts only for less than 10%. Nevertheless, 60–80% of patients, despite evidence of little or no benefit, are treated with antibiotics, contributing to bacterial resistance associated with multiple adverse effects.⁷ Several guidelines and meta-analyses of randomized controlled trials (RCTs) have concluded that antibiotic treatment is mostly ineffective in acute bronchitis, unless the infection is of bacterial origin.⁸

As antibiotics are generally not recommended for acute bronchitis, symptomatic therapy such as antitussives, expectorants, beta-2 agonists, and alternative therapies are commonly prescribed, despite insufficient evidence to support such treatments. There have been the lack of consistent evidence for their use of antitussives on acute bronchitis,⁹ and the evidence regarding the use of expectorants is also questionable.¹⁰ Beta-2 agonists are reported to be effective for patients with airflow obstruction, but adverse events like tremor and nervousness are widely observed.¹¹

Moreover, the Cochrane Reviews suggested a lack of evidence to recommend the use of Chinese herbs in the treatment of acute bronchitis¹² and other alternative therapies, like *Pelargonium sidoides* or ivy leaf extracts are used in various European countries, with variable results.^{13 14}

Thus, there have been substantial efforts worldwide to develop effective therapeutic agents for treating acute bronchitis. In this study, we focused on herbal medicines that have been used for centuries in Oriental countries; we sought to evaluate the efficacy and safety of GHX02, which contains four herbs originating from *gwaruhaengryeon-hwan* (GRHRH) in Donguibogam (Principles and Practice of Eastern Medicine) (Table1). GHX02 has been used for the treatment of patients with acute bronchitis in the Dunsan Korean Medicine Hospital, Daejeon University, and its effectiveness against acute cough has already been demonstrated. We planned a phase 2, multicentre, dose-finding, double-blind, randomized placebo-controlled trial of two different doses of GHX02 compared with placebo. The objective is to compare the GHX02 and placebo in terms of efficacy and safety, and to determine the appropriate dosage of GHX02 required for the treatment of acute bronchitis. We chose a placebo as the control, as this is the most rigorous test for evaluating the efficacy of new medical therapy in a double-blind RCT.¹⁵ In addition, as acute bronchitis is a self-limiting disorder, placebo control is ethically justifiable.

Table1. Components of GHX02

Herb	Latin name	Family name	Part of plant	Amount
Gwaruin	<i>Trichosanthis Semen</i>	Cucurbitaceae	Seed	351mg
Haengin	<i>Armeniacae Semen</i>	Rosaceae	Seed	175.5mg
Hwangryeon	<i>Coptidis Rhizoma</i>	Ranunculaceae	Root stock	175.5mg
Hwangkeum	<i>Scutellariae Radix</i>	Labiatae/Lamiacea	Root	351mg

METHODS AND ANALYSIS

Trial Design

This study is a phase 2, multicentre, dose-finding, double-blind, randomized placebo-controlled trial to evaluate the efficacy and safety of two different doses of GHX02, compared with placebo, for acute bronchitis. The trial will be conducted at three university-affiliated hospitals, including

the Dunsan Korean Medicine Hospital, Daejeon University; the Kyunghee University Korean Medicine Hospital; and the Pusan National University Korean Medicine Hospital. One-hundred and fifty patients will be included in this trial and randomly assigned to either a high-dose GHX02 group (1920mg/day), standard-dose GHX02 group (960mg/day), or control group (placebo) in a 1:1:1 allocation ratio by stratification block randomization of pattern identification. By using the Korean Standard Tool of Pattern Identifications of Cough and Sputum, participants are classified into three patterns: *wind-heat*, *wind-cold*, or *others* (Figure1, Table2). Patients will take one of the medications three times a day for 7 days, with 2 visiting days (day0, day7). This follows the guidelines of the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)¹⁶, Reporting Randomized, Controlled Trials of Herbal Interventions¹⁷ and the trial will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and Consolidated Standards of Reporting Trials (CONSORT) guidelines.¹⁸

Table2. Timetable of study period

TIMEPOINT	STUDY PERIOD			
	Enrolment screening	Allocation Day 0	Post-allocation Day 0 Day 7	
ENROLMENT:				
Eligibility screen	X			
Informed consent	X			
Demographic data	X			
Vital signs	X		X	X
Past history	X			
Concomitant medication	X		X	X
Physical examination & radiography	X			
Laboratory examination	X			X
Pattern identification of cough & sputum	X			
Allocation		X		
INTERVENTIONS:				
High-dose GHX02			←————→	
Standard-dose GHX02			←————→	
Placebo			←————→	
ASSESSMENTS:				
BSS	X		X	X
QCSCS			X	X
LCQ-K-acute			X	X
Frequency of cough fits			←————→	

IMOS, IMPSS				X
Withdrawal rate of patients with exacerbation				X
Concomitant therapy			X	X
Adverse events			X	X
Compliance				X

BSS, Bronchitis Severity Score; QCSCS, Questionnaire on Clinical Symptoms of Cough & Sputum; LCQ-K-acute, Leicester Cough Questionnaire-Korean version-acute; IMOS, Integrative Medicine Outcome Scale; IMPSS, Integrative Medicine Patient Satisfaction Scale

Study Drug and Placebo

GHX02 is a combination of the following four herbs: Gwaruin (*Trichosanthis Semen*, 351 mg/tablet), Haengin (*Armeniacae Semen*, 175.5 mg/tablet), Hwangryeon (*Coptidis Rhizoma*, 175.5 mg/tablet), Hwangkeum (*Scutellariae Radix*, 351 mg/tablet) (Table 1). One GHX02 tablet (500mg/tablet) contains 160.0mg of dry extract of the four herbs (obtained by boiling in water and then dehydrating) mixed with 340.0mg of starch and lactose. The placebo tablet does not contain any of these active ingredients but is matched in terms of colour, smell, and taste. The dosage was determined according to the Pharmacologically Active Dose (PAD) in expectorant effective tests. Both tablets are pink and round and will be provided by Hankookshinyak Corporation (Nonsan, Korea). The manufacturer complies with the provisions of the Regulations on the Safety of Pharmaceuticals and will manage the quality appropriately. Safety and toxicological tests of GHX02 will be conducted simultaneously. All allocated patients will be prescribed 4 tablets of either the clinical medicine or placebo to be administered three times daily for 7 days, and the number of remaining tablets will be recorded on day 7 to calculate compliance. To improve compliance, participants will be asked to record their daily dosage in the cough diary. The overall medication compliance during the trial should be at least 75%; if the medication compliance is less than 75%, the participant will be considered inadequate and excluded from the per-protocol (PP) analysis group.

Sample size

The estimated sample size required for this study is 150 patients (50 patients per group).¹⁹ The estimation of the number of subjects is based on whether there is a difference in the change from

1
2
3
4 baseline (day 0) to post-dose (day 7) BSS, between the control and standard-dose GHX02 group.
5 In an earlier comparable clinical study, the difference was reported to be 2.3, and the standard
6 deviation of the changes in BSS, was estimated to be 3.2.²⁰ The power to detect the difference
7 was assumed to be 0.8, and the two-sided significance level was 0.05. The ratio of allocation of
8 subjects between the groups was 1:1:1, and dropout rate was presumed to be 0.2.
9
10
11
12
13
14

15 **Recruitment**

16
17 Participants will be recruited from the outpatient departments (OPDs) of the affiliated hospitals by
18 posting brochures in a well visible place in front of the clinic and distributing it to every patient
19 visiting OPDs of pulmonology. Recruitment will commence in January 2018.
20
21
22
23
24

25 **Participants**

26 Inclusion criteria

27
28 Potential participants who meet the following criteria will be included in this trial: (1) age 19–75
29 years; (2) BSS \geq 5 points at day 0 due to acute bronchitis; (3) symptoms starting within 2 weeks
30 before study inclusion; (4) patients who consent to participate. Diagnoses of acute bronchitis will
31 be based on patients' medical history, physical examinations, and BSS, including cough, sputum,
32 dyspnea, chest pain during coughing, and rales on auscultation.
33
34
35
36
37
38
39
40

41 Exclusion criteria

42
43 Patients with any of the following criteria will be excluded from this trial: (1) pregnant or breast-
44 feeding; (2) treatment with antibiotics, bronchodilators, glucocorticoids, immune-depressants, or
45 other clinical trial medicines during the last 4 weeks before study inclusion; (3) treatment with
46 antitussives or expectorants during the last 7 days before study inclusion; (4) history or presence
47 of confounding respiratory disease that may affect evaluation of the efficacy of clinical medicine
48 (e.g. chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, asthma,
49 pneumonia, cystic fibrosis, lung cancer, or active pulmonary tuberculosis); (5) liver or renal
50
51
52
53
54

1
2
3
4 impairment (alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline
5 phosphatase [ALP] ≥ 2 times the normal upper limit, or creatinine > 3.0 mg/dL at screening); (6)
6 history or presence of clinically relevant cardiovascular, renal, metabolic, haematological,
7 neurological, psychiatric, systemic, infectious disease, or malignant tumour (except where there is
8 no recurrence for more than 5 years after surgery); (7) genetic problems such as galactose
9 intolerance, Lapp lactose deficiency or glucose-galactose malabsorption; (8) history of alcoholism
10 or substance abuse; (9) participation in other clinical medicine trials during the last 30 days before
11 study inclusion; (10) judged by the investigators to be inappropriate for the clinical trial.
12 Additional treatment will not be permitted during the trial, and participants are recommended not
13 to alter their exercise pattern or diet. Drugs that may affect bronchitis symptoms or that have a
14 similar therapeutic purpose to the trial medication will not be permitted, including antibiotics,
15 bronchodilators, glucocorticoids, immune-depressants, antitussives, expectorants or any other
16 clinical trial medicine. Those who require or take these concomitant medicines during the trial will
17 be excluded from this study. Other medications will only be permitted at the discretion of the
18 investigators. All drug information (name of product, purpose of administration, dosage, duration
19 of administration, etc.) will be recorded on the patient case report form (CRF).
20
21
22
23
24
25
26
27
28
29
30
31

32 Randomization and allocation concealment

33
34 An independent statistician will conduct randomization, using a computer random number
35 generator of SAS[®] Analytics Pro (SAS Institute, Inc., Cary, North Carolina, USA). Allocation will be
36 implemented by the manufacturers who collectively label participant's identification code on the
37 packages of the test drug or a placebo using generated random numbers. This labeled drug will
38 be given to the management pharmacist. When the investigator requests medication, the
39 management pharmacist gives the participant the drug corresponding to the participant's
40 identification code. Only the statistician and manufacturer have access to the random numbers,
41 and they will sign and submit a written non-disclosure agreement. After that, just the
42 identification code is used to identify which drug to give to which participant. We will allocate
43 three groups (*wind-heat*, *wind-cold*, or *others*) at a 1:1:1 ratio of high-dose, standard-dose, and
44 placebo treatment. Stratified block randomization using the Korean Standard Tool of Pattern
45 Identifications of Cough and Sputum will be performed in this trial.
46
47
48
49
50
51
52
53
54

Korean Standard Tool of Pattern Identifications of Cough and Sputum

The Korean Standard Tool of Pattern Identifications of Cough and Sputum is used to identify patterns of acute bronchitis patients. This pattern identification is an important diagnostic criterion in Korean medicine which is used for deciding medication and other therapies. It was proposed in the Traditional Korean Medicine Clinical Practice Guidelines for Antitussives and Expectorants for Korean Medical Diagnostic Standards.²¹ This comprises 56 items to classify cases into three patterns: *wind-cold*, *wind-heat* or *others*. We will investigate the correlation between the patterns and the efficacy of GHX02; the *wind-heat* patterns group is expected to show greater response than the other groups to the therapeutic effects of GHX02.

Blinding

This is a double-blind trial, thus neither participants nor investigators (including outcome assessors) will be aware of group assignment until the end of the study period. Placebo tablets will be matched to GHX02 tablets in terms of colour, taste, and smell, as well as outer packaging. Elimination of blindness will only be considered in cases of serious medical emergencies.

Outcome measures

Primary outcome

Bronchitis Severity Score

The BSS was developed as an evaluation tool for acute bronchitis in 1996 and was recently shown to be valid and reliable by the European Medicines Agency's Committee on Herbal Medicinal Products (HMPC).²⁰ It has been used successfully in many clinical trials for acute bronchitis. BSS comprises the sum of five major symptom scores for acute bronchitis: cough, sputum, dyspnea, chest pain during coughing, and rales on auscultation. Each symptom is scored on a 4-point-scale (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe), with a maximum total score of 20 points. The investigator assesses symptom scores on the basis of the patient's subjective symptoms, and this correlates highly with the patient's actual improvement, as acute bronchitis mainly involves subjective complaints.²² The change in BSS between day 0 and day 7 will be the

1
2
3
4 primary outcome of this trial.
5
6
7

8
9 Secondary outcomes

10
11 Assessment of acute bronchitis predominantly depends on subjective tools, but more reliable data
12 can be derived if appropriate objective variables are used together. Symptom and quality of life
13 (QOL) questionnaires will be used as subjective tools, whereas cough frequency will be used as an
14 objective tool; among outcome measures of cough symptoms, only cough frequency and quality
15 of life questionnaires have been shown to be valid.²³
16
17
18

19
20
21
22 *Questionnaire of Clinical Symptoms of Cough and Sputum*
23

24 The Questionnaire of Clinical Symptoms of Cough and Sputum (QCSCS) was proposed as a
25 primary outcome measure in the Traditional Korean Medicine Clinical Practice Guidelines for
26 Antitussives and Expectorants²¹ and was developed by remodelling the Clinical Asthma
27 Measurement Scale in Oriental Medicine-V for cough and sputum.²⁴ It is also appropriate for
28 preparing clinical trials of GHX02 as an Investigational New Drug (IND), as it is the suggested tool
29 in Clinical Practice Guidelines from the Ministry of Food and Drug Safety in Korea. Questionnaire
30 items are as follows: (1) cough – frequency, intensity, sensitivity; (2) sputum – frequency, volume,
31 difficulty to cough-up, appearance, colour; (3) activities of daily living; (4) night-time sleeping.
32 Each item is scored on a 4-point-scale, with a total maximum score of 40 points. This
33 questionnaire can evaluate symptoms of cough and sputum more specifically and in more detail
34 than the BSS. The changes in QCSCS from day0 to day7 will be analysed for a secondary outcome.
35
36
37
38
39
40
41
42
43
44

45 *Leicester Cough Questionnaire*
46

47 The Leicester Cough Questionnaire (LCQ-K-acute) evaluates quality of life associated with cough. It
48 consists of 19 items divided into three parts, physical, psychological, and social, each scored from
49 1 to 7. The total score is the sum of the average scores (1–7 points) for each part. The higher the
50 score, the better the quality of life. Although it was initially developed as an assessment tool for
51 chronic cough, it has also been found to be useful for acute cough, by changing the time criteria
52
53
54

1
2
3
4 from 2 weeks to 24 hours.²⁵ In addition, the validity and reliability of the Korean version of the
5 LCQ(LCQ-K) has already been verified.²⁶ The changes of LCQ-K-acute between day0 and day7 will
6 be evaluated.
7
8
9

10 11 12 *Frequency of coughing fits*

13
14 Coughing frequency is an objective measurement tool for evaluating coughing. In this trial, we will
15 ask participants to record how often they cough each day. A cough diary will be given to record
16 their everyday coughing frequency, and participants will be classified into one of the following
17 scales: 0 = 0 time/day, 1 = 1 time/day, 2 = 2-3 times/day, 3 = 4-5 times/day(sometimes), 4 = 6-10
18 times/day(frequent), 5 = over 15 times/day(consistently).²⁷ We will evaluate the frequency of
19 coughing fits daily from day0 to day7 and analyse the changes in frequency of coughing fits after
20 1-7days from the baseline. (change in frequency of coughing fits after k days of study =
21 frequency of coughing fits after k days of study - frequency of coughing fits at day0, where k = 1,
22 2, ..., 7)
23
24
25
26
27
28
29
30

31 *Integrative Medicine Outcome Scale and Integrative Medicine Patient Satisfaction Scale*

32
33 The Integrative Medicine Outcome Scale is a 5-point-scale for evaluating improvement after
34 treatment (where, 1=complete recovery, 2=major improvement, 3=slight-to-moderate
35 improvement, 4=no change, 5=deterioration), either by the patient or investigator (the
36 investigator in this trial). The Integrative Medicine Patient Satisfaction Scale is a 5-point-scale for
37 evaluating patient satisfaction with the treatment (where, 1=very satisfied, 2=satisfied, 3=neutral,
38 4=dissatisfied, 5=very dissatisfied).²⁰ Both will be measured at the patients' final visit (day7) and
39 will be analysed for a secondary outcome.
40
41
42
43
44
45
46
47

48 *Withdrawal rate of patients with exacerbation*

49
50 Exacerbation in this trial means progression of acute bronchitis to bacterial bronchitis or
51 pneumonia, requiring concomitant medicine such as antibiotics, bronchodilators, glucocorticoids,
52 etc. During the trial, patients will be asked to inform about any signs of worsening symptoms, and
53
54

1
2
3
4 investigators will evaluate appropriate measures if they need additional therapy. Those who
5 require concomitant medicines will be excluded from the trial and provided the necessary
6 medicine. We will calculate this withdrawal rate in each intervention and control group to check
7 the relevance with drug effects.
8
9

10 11 12 13 **Safety assessment**

14
15 Safety will be assessed in terms of adverse events (AEs), vital signs, and laboratory examinations
16 (liver function test and routine blood and urine tests). AEs and vital signs will be recorded on a
17 CRF at every visit, and laboratory examinations will be conducted before and after taking the
18 medication. AEs are defined as every unexpected sign or symptom during the trial period and
19 participants are asked to inform about any of these AEs during medication. All information about
20 AEs will be recorded in detail, such as the duration and extent of the AE, relationship with the trial
21 medicine, name of the suspected drug, etc. Common adverse events may include gastrointestinal
22 side-effects, such as anorexia, stomach discomfort, nausea, and diarrhoea, which are not expected
23 to be severe. However, if serious AEs occur that may lead to death or require extended
24 hospitalization, the patient will be removed from the clinical trial as soon as possible and proper
25 treatment will be provided (Table2).
26
27
28
29
30
31
32
33
34
35

36 **Data management and monitoring**

37
38 The investigators will follow the Standard Operating Procedures (SOP) of the trial for a better
39 quality of assessment and collection of outcome data. The investigators who evaluate outcome
40 measures should be restricted to only physicians who have attended the training meetings. All
41 assessment data and case reports will be collected at baseline (day0) and at the end of the trial
42 (day7) in both the intervention and control groups. Collected documents and data will be
43 managed by electronic CRF and encrypted using double data entry. Only the principle investigator,
44 or those who have permission, will be able to access the data. The CRFs and other documents will
45 be stored at a separate and secure location for 10 years after trial completion.
46
47
48
49
50

51 Multicentre clinical trial monitoring will be conducted via regular visits (every one-fourth of
52 recruitment) and occasional telephone calls. The information collected will be reported to the data
53
54

1
2
3
4 monitoring committee (DMC), comprising specialists in pulmonology and medical statistics who
5 are unrelated to this trial. At visits, a monitor will confirm whether the trial is being conducted in
6 accordance with the protocol and especially AEs are being properly reported and recorded on
7 CRFs. The monitor will check the whole process of the clinical trial and problems will be discussed
8 with the investigator as and when they occur.
9
10
11
12
13
14

15 **Statistical analysis**

16
17 Data analysis will be performed by an independent statistician using SAS[®] Analytics Pro.
18 Continuous variables will be summarized by Mean \pm SD, and categorical variables will be reported
19 with frequencies and percentages according to three treatment groups. Efficacy evaluation will be
20 primarily based on the intention-to-treat (ITT) analysis, and per-protocol (PP) analysis will be used
21 as a secondary analysis. ITT analysis will be conducted for all subjects randomized, and PP analysis
22 will be conducted for those who completed the entire trial without violating the protocol. For
23 primary outcome analysis, the changes in BSS between day0 and day7 will be evaluated using
24 analysis of covariance (ANCOVA) which contains the day0's BSS and the treatment group as
25 covariates. Significance will be accepted at a two-sided test with α -level of 0.05. For effects of
26 GHX02 treatments compared with the control group, 95% confidence intervals (CIs) will be
27 calculated. Analyses of secondary outcomes will be carried out as follows: QCSCS and LCQ-K-
28 acute by ANCOVA including its baseline value respectively; frequency of coughing fits by linear
29 mixed models (LMMs); IMOS and IMPSS by analysis of variance (ANOVA); and withdrawal rate of
30 patients with exacerbation by Pearson's chi-squared or Fisher's exact tests. To handle missing
31 values when processing ITT analysis, the last-observation-carried-forward (LOCF) method will be
32 used except for frequency of coughing fits analysed with LMMs in which missing values need not
33 to be imputed.
34
35
36
37
38
39
40
41
42
43

44 Safety assessment will be performed by ITT analysis; all participants randomized will be included.
45 Comparison of the number of adverse events between three treatment groups will be performed
46 using Kruskal-Wallis tests. Demographic and baseline data will be analysed using ANOVA for
47 continuous variables, and Pearson's chi-squared or Fisher's exact tests for categorical variables.
48
49
50
51
52
53
54

ETHICS AND DISSEMINATION

The trial protocol (version 1.0) has been approved by the Institutional Review Board (IRB) of the Dunsan Korean Medicine Hospital, Daejeon University (No. DJDSKH-17-DR-14) and has been registered through the clinical trials registry (NCT03310385). If the protocol needs modifications, the investigators are required to inform the IRB (as well as participants) and receive re-approval. Before the trial, investigators are required to provide all information related to the clinical trial, including the possible benefits and risks, other therapeutic choices, and right to withdraw, via a written consent form approved by the IRB. After being provided with sufficient time and opportunity to ask questions and decide whether to participate, all participants are required to provide written consent before study inclusion. All patient identifiable data will be kept confidential, even when the results of the trial are published and participant information will be stored in a secure file, and only the primary investigator (including those who have permission) and the monitor will have access to the data. To ensure confidentiality, all clinical trial documents, such as CRFs, will be recorded and distinguished by the participant identification number throughout the trial. At the end of the trial, the study results will be disseminated via peer-reviewed journals, conference presentation and the Clinical Research Information Service; the participants will also be informed of the results, even unpublished data, including missing data.

DISCUSSION

Despite problems associated with antibiotic abuse in public health systems and the substantial economic burden associated with acute bronchitis, currently no definitive medication is recommended. There are many studies exploring the efficacy of herbal medicines; a systematic review concluded that there was insufficient evidence to support the use of Chinese herbs for acute bronchitis because of the high risk of bias and lack of toxicological evidence.¹² This study is a multicentre, double-blind, randomized placebo-controlled trial to evaluate the efficacy and safety of two different doses of GHX02, compared with placebo, for acute bronchitis, and we followed strict quality control methods. To ensure a well-designed trial, we conducted a systematic review of randomized controlled trials for acute bronchitis in the last 10 years.²⁸

There are some strengths and limitations to this protocol. Contrary to other trials, we will use the Korean Standard Tool of Pattern Identifications of Cough and Sputum, which is a Korean Medical

1
2
3
4 Diagnostic Standard for categorizing cases, to obtain additional information as to whether a
5 certain categories of patients respond better than others to treatment. In this way, we will be able
6 to investigate the efficacy of GHX02 for more specific categories of people suffering from acute
7 bronchitis. Another strength is that the outcome measures we will use in this trial is well balanced
8 between patients' subjective and objective outcomes; thus, the effectiveness of GHX02 will be
9 demonstrated from various aspects. As GHX02 is an herbal prescription which has already been
10 used for acute bronchitis, there is little risk of side-effects and the efficacy of GHX02 is already
11 proven by empirical evidence. This study will provide new evidence for the efficacy and safety of
12 GHX02 in a standard research design and is expected to be presented as a recommended
13 alternative medicine for acute bronchitis.
14
15
16
17
18
19

20 A limitation of this trial protocol is that we will only target adults, despite most acute bronchitis
21 patients being children under 5 years. As clinical drug trials are recommended to be first applied
22 to adults, we selected adults aged between 19 and 75 years. Further studies for children will need
23 to be conducted after completion of this study.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Author affiliations

1 Division of Respiratory System, Dept. of Internal Medicine, College of Korean Medicine, Daejeon University

2 East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University

3 Institute of Traditional Medicine and Bioscience, Daejeon University

4 Dept. of Applicative Statistics, College of Economics, Daejeon University

5 Dept. of Neuropsychology, College of Korean Medicine, Daejeon University

Acknowledgements

The authors thank the staff and patients participating in the study. Additionally, the authors thank the staff at Daejeon University Dunsan Korean Medicine Hospital Clinical Trial Center (DCTC), especially Da Yeong Lee for overview of the research. We also thank Ju Ah Lee for writing and drawing up the protocol.

Contributors

YRL drafted the research protocol and wrote the manuscript. WKY, SJP, SHK were involved in the protocol development. WK contributed to the statistical design and analysis. ICJ and YCP supervised this protocol. All authors contributed to the conception and implementation of this clinical trial.

Funding

This research was supported by the National Research Foundation of Korea Grant funded by the Korean Government (NRF-2015R1D1A1A01058852), the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (grant number: HI15C0006), and Korea Institute of Oriental Medicine (grant number: K17510).

Competing interests

None declared.

Ethics approval

The protocol was approved by the Institutional Review Board of Dunsan Korean Medicine Hospital, Daejeon University.

Provenance and peer review

Not commissioned; externally peer reviewed.

REFERENCES

1. Wenzel RP, Fowler III AA. Acute bronchitis. *New England journal of medicine* 2006;355(20):2125-30.
2. Park MJ, Rhee CK, Kim YH, et al. Efficacy and safety of HL301 in the treatment of acute bronchitis and acute exacerbation of chronic bronchitis: a phase 2, randomized, double-blind, placebo-controlled, multicenter study. *Current Medical Research and Opinion* 2017;33(5):919-25.
3. Kamin W, Ilyenko LI, Malek FA, et al. Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents. *Pediatrics International* 2012;54(2):219-26.
4. Tackett KL, Atkins A. Evidence-based acute bronchitis therapy. *Journal of pharmacy practice* 2012;25(6):586-90.
5. Kinkade S, Long NA. Acute Bronchitis. *American family physician* 2016;94(7)
6. Albert RH. Diagnosis and treatment of acute bronchitis. *American family physician* 2010;82(11)
7. Steinman MA, Sauaia A, Maselli JH, et al. Office evaluation and treatment of elderly patients with acute bronchitis. *Journal of the American Geriatrics Society* 2004;52(6):875-79.
8. Smith SM, Smucny J, Fahey T. Antibiotics for acute bronchitis. *Jama* 2014;312(24):2678-79.
9. Braman SS. Chronic cough due to acute bronchitis: ACCP evidence-based clinical practice guidelines. *CHEST Journal* 2006;129(1_suppl):95S-103S.
10. Smith SM, Schroeder K, Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings. *Cochrane Database Syst Rev* 2012;8(8)
11. Cayley Jr WE. Beta2 Agonists for Acute Cough or a Clinical Diagnosis of Acute Bronchitis. *American family physician* 2017;95(9):551.
12. Jiang L, Li K, Wu T. Chinese medicinal herbs for acute bronchitis. *The Cochrane Library* 2012
13. Timmer A, Günther J, Motschall E, et al. Pelargonium sidoides extract for treating acute respiratory tract infections. *The Cochrane Library* 2013
14. Holzinger F, Chenot J-F. Systematic review of clinical trials assessing the effectiveness of ivy leaf (*hedera helix*) for acute upper respiratory tract infections. *Evidence-Based Complementary and Alternative Medicine* 2010;2011
15. Castro M. Placebo versus best-available-therapy control group in clinical trials for pharmacologic therapies: which is better? *Proceedings of the American Thoracic Society* 2007;4(7):570-73.
16. Moher D, Chan AW. SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials). *Guidelines for Reporting Health Research: A User's Manual* 2014:56-67.
17. Cheng C-w, Wu T-x, Shang H-c, et al. CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration. *Annals of internal medicine* 2017;167(2):112-21.

18. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMC medicine* 2010;8(1):18.
19. Chow S, Shao J. Wang, Sample Size Calculations In Clinical Research: Taylor & Francis, NY, 2003.
20. Matthys H, Kamin W. Positioning of the Bronchitis Severity Score (BSS) for standardised use in clinical studies. *Current medical research and opinion* 2013;29(10):1383-90.
21. Ministry of Food and Drug Safety, Herbal medicine Evaluation Department. The Traditional Korean Medicine Clinical Practice Guidelines for Antitussives and Expectorants. Seoul: Ministry of Food and Drug Safety 2007:5-15.
22. Lehl S, Matthys H, Kamin W, et al. The BSS—a valid clinical instrument to measure the severity of acute bronchitis. *Pulm Respir Res* 2014;1:00016.
23. Leconte S, Ferrant D, Dory V, et al. Validated methods of cough assessment: a systematic review of the literature. *Respiration* 2011;81(2):161-74.
24. Baek H-j, Lee B-j, Jung S-k, et al. Retrospective Study of Patients with Cough Treated with Eunhwayeongyo-tang. *The Journal of Internal Korean Medicine* 2016;37(6):961-77.
25. Yousaf N, Lee KK, Jayaraman B, et al. The assessment of quality of life in acute cough with the Leicester Cough Questionnaire (LCQ-acute). *Cough* 2011;7(1):4.
26. Han J-M, Jung I-C, Kang W, et al. Reliability and validity of leicester cough questionnaire Korean version. *Chronic respiratory disease* 2014;11(3):147-52.
27. Fischer J, Dethlefsen U. Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial. *Cough* 2013;9(1):25.
28. Lyu Y, Lee EJ, Jeon JH, et al. A Systemic Review of Clinical Trials Using Medication for Acute Bronchitis: A Pre-study on the Development of Traditional Korean Medicine Clinical Practice Guideline. *Journal of Korean Medicine* 2017;38(1):93-111.

FIGURE LEGENDS

Figure 1. Flowchart of the study procedure




Figure1. Flowchart of the study procedure

Figure1. Flowchart of the study procedure

81x60mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	p.1,line1-3
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	p.2,line26/ p.14,line5
	2b	All items from the World Health Organization Trial Registration Data Set	p.5,line8-12
Protocol version	3	Date and version identifier	p.14,line2
Funding	4	Sources and types of financial, material, and other support	p.16,line18-22
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	p.16,line13-16
	5b	Name and contact information for the trial sponsor	p.16,line18-22
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	-
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	p.14,line1-4

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47**Introduction**

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	p.3,line10-p.4,line16
	6b	Explanation for choice of comparators	p.4,line14-16
Objectives	7	Specific objectives or hypotheses	p.4,line12-14
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	p.4,line27-29

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	p.4,line29-p.5,line2, p.7,line9-11
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	p.7,line13-p.8,line18
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	p.6,line22-24
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	p.8,line10-14/ p9,line15/ p11,line25-p.12,line4
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	p.6,line25-26
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	p.8,line10-16
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	p.9,line18-p.12,line4

1				
2				
3	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	p.5,line13-p.6,line9
4				
5	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	p.6,line30-p.7,line5
6				
7				
8	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	p.7,line7-10
9				
10				

11 **Methods: Assignment of interventions (for controlled trials)**

12 Allocation:

13				
14				
15	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	p.8,line19-20/25-27/29-30
16				
17				
18				
19				
20	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	p.8,line20-23
21				
22				
23				
24	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	p.8,line23-27
25				
26				
27	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	p.9,line12-13
28				
29				
30		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	p.9 ,line15
31				
32				
33				

34 **Methods: Data collection, management, and analysis**

35				
36	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	p.12,line20-24
37				
38				
39				
40				
41				
42				

1			
2			
3		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols
4			p.6,line25-26
5			
6	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol
7			p.12,line24-26
8			
9			
10	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol
11			p.13,line10-21
12			
13		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)
14			p.13,line18-21
15		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)
16			p.13,line21-24
17			
18	Methods: Monitoring		
19			
20	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed
21			p.12,line28-p.13,line5
22			
23			
24			
25		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial
26			p.12,line15-17/ p.11,line25-p.12,line4
27			
28	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct
29			p.12,line11-17 / p.13,line2-4
30			
31	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor
32			p.12,line28-p.13,line5
33			
34			
35	Ethics and dissemination		
36			
37	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval
38			p.14,line2-4
39			
40			
41			
42			
43			
44			
45			
46			
47			

1				
2				
3	Protocol	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	p.14,line4-5
4	amendments			
5				
6				
7	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	p.14,line6-10
8				
9				
10		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	p.14,line6-10
11				
12				
13	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	p.14,line10-15
14				
15				
16	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	p.16,line24-25
17				
18				
19	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	p.14,line12-13
20				
21				
22	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	p.12,line15-17
23				
24				
25	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	p.14,line15-17
26				
27				
28				
29		31b	Authorship eligibility guidelines and any intended use of professional writers	p.16,line13-16
30				
31		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	p.14,line15-17
32				
33	Appendices			
34				
35	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	-
36				
37				
38	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	p.12,line26-27
39				
40				
41				
42				
43				
44				
45				
46				
47				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

For peer review only

BMJ Open

Efficacy and safety of GHX02 in the treatment of acute bronchitis: protocol of a phase 2, double-blind, randomized placebo-controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019897.R3
Article Type:	Protocol
Date Submitted by the Author:	05-Mar-2018
Complete List of Authors:	Lyu, Yee Ran; College of Korean Medicine, Daejeon University, Division of Respiratory System, Dept. of Internal Medicine Yang, Won-Kyung ; Institute of Traditional Medicine and Bioscience, Daejeon University Park, So Jung ; Dunsan Korean Medicine Hospital of Daejeon University, East West Cancer Center Kim, Seung-Hyeong; Institute of Traditional Medicine and Bioscience, Daejeon University Kang, Wee-Chang; College of Economics, Daejeon University, Dept. of Applicative Statistics Jung, In Chul; College of Korean Medicine, Daejeon University, Dept. of Neuropsychology Park, Yang Chun; College of Korean Medicine, Daejeon University, Division of Respiratory System, Dept. of Internal Medicine
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Respiratory medicine
Keywords:	acute bronchitis, Herbal medicine < THERAPEUTICS, GHX02, randomized controlled trial

SCHOLARONE™
Manuscripts

1
2
3
4 **Efficacy and safety of GHX02 in the treatment of acute bronchitis:**
5
6 **protocol of a phase 2, double-blind, randomized placebo-**
7 **controlled trial**
8
9

10
11
12
13 Yee Ran Lyu¹, Won-Kyung Yang^{1,3}, So Jung Park², Seung-Hyung Kim³,
14 Weechang Kang⁴, In Chul Jung⁵, Yang Chun Park^{1*}
15

16
17
18 ¹ Division of Respiratory System, Dept. of Internal Medicine, College of Korean Medicine, Daejeon
19 University
20

21 ² East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University
22

23 ³ Institute of Traditional Medicine and Bioscience, Daejeon University
24

25 ⁴ Dept. of Applicative Statistics, College of Economics, Daejeon University
26

27 ⁵ Dept. of Neuropsychology, College of Korean Medicine, Daejeon University
28

29 **Correspondence to**

30 Professor Yang-Chun Park, omdpyc@dju.kr

31 Korean Internal Medicine and Director of the Clinical Trial Center

32 Dunsan Korean Medicine Hospital of Daejeon University

33 75, Daedeok-daero 176-beongil, Seo-gu, Daejeon, Republic of Korea 35235

34 Tel: 82-42-470-9126 (clinic), 82-42-229-6763 (office, Munchang Campus)

35 Fax: 82-42-470-9486
36
37
38
39
40

41 Word count : 3939
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Acute bronchitis is a self-limiting infection of the large airways; cough is the primary symptom, usually lasting for about 3 weeks. Annually, approximately 5% of adults develop acute bronchitis, and its economic burden is substantial. There are also problems of antibiotic abuse in public health systems and symptomatic therapies are commonly prescribed, for which there is insufficient supporting evidence. GHX02 contains four herbs originating from *gwaruhaengryeon-hwan*, which has been used in the treatment of acute bronchitis patients in Korea. The objective is to compare the GHX02 and placebo in terms of efficacy and safety, and to determine the appropriate dosage.

Methods and analysis: We planned a phase 2, multicentre, dose-finding, double-blind, randomized placebo-controlled trial of two different doses of GHX02 compared with placebo. A total of 150 patients, aged 19-75 years, with a Bronchitis Severity Score (BSS) ≥ 5 due to acute bronchitis starting within 2 weeks of study enrolment will be recruited from three university-affiliated hospitals across Korea. Participants will be stratified into three patterns using the Korean Standard Tool of Pattern Identifications of Cough and Sputum and randomly assigned to either a high-dose GHX02 group (1,920mg/day), standard-dose GHX02 group (960mg/day), or placebo group according to a 1:1:1 allocation ratio. Patients will take medications three times daily for 7 days, with 2 visiting days. The primary outcome measure is a change in BSS from day 0 to day 7. The secondary outcomes are the Questionnaire of Clinical Symptoms of Cough and Sputum, Leicester Cough Questionnaire, frequency of coughing fits, Integrative Medicine Outcome Scale, Integrative Medicine Patient Satisfaction Scale and withdrawal rate of patients with exacerbation. Safety will be assessed by adverse events, vital signs, and laboratory examinations.

Ethics and dissemination: The study has been approved by our Institutional Review Board (No. DJDSKH-17-DR-14). The trial results will be disseminated via peer-reviewed journals and the Clinical Research Information Service.

Trial registration number: NCT03310385

KEY WORDS: acute bronchitis, herbal medicine, GHX02, randomized controlled trial

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This study will provide new evidence for the efficacy and safety of GHX02 in a standard research design

- We will use the Korean Standard Tool of Pattern Identifications of Cough and Sputum, via stratified block randomization
- This is a well-designed study and the outcome measures are well balanced between patients' subjective and objective outcomes
- Limitation is that this trial protocol only targets adults
- This clinical trial is limited in that complete remission of acute bronchitis could not be observed due to the short trial period

INTRODUCTION

Acute bronchitis is the most common disease seen in outpatient departments (OPDs) across South Korea; about 5% of the general population have acute bronchitis.¹ In 2016, the Health Insurance Review & Assessment Service of South Korea estimated that more than 1500 million people visited OPDs for acute bronchitis and that the rate of increase in medical expenses, compared to that over the previous year, also rose.² Thus, acute bronchitis represents a substantial economic burden on the public health system, and effective therapeutic agents are urgently required.³

Acute bronchitis is a self-limiting infection of the large airways, with cough as the primary symptom, usually lasting for about 3 weeks.⁴ It is characterized by acute onset of cough, accompanied by the production of sputum and dyspnea or chest discomfort.⁵ As there are no specific diagnostic criteria for acute bronchitis, diagnosis is primarily clinical and requires a thorough assessment to differentiate from pneumonia, common cold, and asthma.⁶ Up to 90% of acute bronchitis is caused by viruses; bacterial infection accounts only for less than 10%. Nevertheless, 60–80% of patients, despite evidence of little or no benefit, are treated with antibiotics, contributing to bacterial resistance associated with multiple adverse effects.⁷ Several guidelines and meta-analyses of randomized controlled trials (RCTs) have concluded that antibiotic treatment is mostly ineffective in acute bronchitis, unless the infection is of bacterial origin.⁸

As antibiotics are generally not recommended for acute bronchitis, symptomatic therapy such as antitussives, expectorants, beta-2 agonists, and alternative therapies are commonly prescribed, despite insufficient evidence to support such treatments. There have been the lack of consistent evidence for their use of antitussives on acute bronchitis,⁹ and the evidence regarding the use of expectorants is also questionable.¹⁰ Beta-2 agonists are reported to be effective for patients with airflow obstruction, but adverse events like tremor and nervousness are widely observed.¹¹

Moreover, the Cochrane Reviews suggested a lack of evidence to recommend the use of Chinese herbs in the treatment of acute bronchitis¹² and other alternative therapies, like *Pelargonium sidoides* or ivy leaf extracts are used in various European countries, with variable results.^{13 14}

Thus, there have been substantial efforts worldwide to develop effective therapeutic agents for treating acute bronchitis. In this study, we focused on herbal medicines that have been used for centuries in Oriental countries; we sought to evaluate the efficacy and safety of GHX02, which contains four herbs originating from *gwaruhaengryeon-hwan* (GRHRH) in Donguibogam (Principles and Practice of Eastern Medicine) (Table 1). GHX02 has been used for the treatment of patients with acute bronchitis in the Dunsan Korean Medicine Hospital, Daejeon University, and its effectiveness against acute cough has already been demonstrated. We planned a phase 2, multicentre, dose-finding, double-blind, randomized placebo-controlled trial of two different doses of GHX02 compared with placebo. The objective is to compare the GHX02 and placebo in terms of efficacy and safety, and to determine the appropriate dosage of GHX02 required for the treatment of acute bronchitis. We chose a placebo as the control, as this is the most rigorous test for evaluating the efficacy of new medical therapy in a double-blind RCT.¹⁵ In addition, as acute bronchitis is a self-limiting disorder, placebo control is ethically justifiable.

Table 1. Components of GHX02

Herb	Latin name	Family name	Part of plant	Amount
Gwaruin	<i>Trichosanthis Semen</i>	Cucurbitaceae	Seed	351mg
Haengin	<i>Armeniaca Semen</i>	Rosaceae	Seed	175.5mg
Hwangryeon	<i>Coptidis Rhizoma</i>	Ranunculaceae	Root stock	175.5mg
Hwangkeum	<i>Scutellariae Radix</i>	Labiatae/Lamiacea	Root	351mg

METHODS AND ANALYSIS

Trial Design

This study is a phase 2, multicentre, dose-finding, double-blind, randomized placebo-controlled trial to evaluate the efficacy and safety of two different doses of GHX02, compared with placebo, for acute bronchitis. The trial will be conducted at three university-affiliated hospitals, including

the Dunsan Korean Medicine Hospital, Daejeon University; the Kyunghee University Korean Medicine Hospital; and the Pusan National University Korean Medicine Hospital. One-hundred and fifty patients will be included in this trial and stratified into three patterns (*wind-heat*, *wind-cold*, or *others*) by using the Korean Standard Tool of Pattern Identifications of Cough and Sputum. Then, each pattern of patients will randomly assigned to either a high-dose GHX02 group (1920mg/day), standard-dose GHX02 group (960mg/day), or control group (placebo) in a 1:1:1 allocation ratio. Stratified block randomization using the pattern identification will be performed in this trial as above (Figure1, Table2). Patients will take one of the medications three times a day for 7 days, with 2 visiting days (day0, day7). This follows the guidelines of the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)¹⁶, Reporting Randomized, Controlled Trials of Herbal Interventions¹⁷ and the trial will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and Consolidated Standards of Reporting Trials (CONSORT) guidelines.¹⁸

Table2. Timetable of study period

TIMEPOINT	STUDY PERIOD			
	Enrolment screening	Allocation Day 0	Post-allocation Day 0 Day 7	
ENROLMENT:				
Eligibility screen	X			
Informed consent	X			
Demographic data	X			
Vital signs	X		X	X
Past history	X			
Concomitant medication	X		X	X
Physical examination & radiography	X			
Laboratory examination	X			X
Pattern identification of cough & sputum	X			
Allocation		X		
INTERVENTIONS:				
High-dose GHX02			←————→	
Standard-dose GHX02			←————→	
Placebo			←————→	
ASSESSMENTS:				
BSS	X		X	X
QCSCS			X	X
LCQ-K-acute			X	X

Frequency of cough fits			←————→
IMOS, IMPSS			X
Withdrawal rate of patients with exacerbation			X
Concomitant therapy		X	X
Adverse events		X	X
Compliance			X

BSS, Bronchitis Severity Score; QCSCS, Questionnaire on Clinical Symptoms of Cough & Sputum; LCQ-K-acute, Leicester Cough Questionnaire-Korean version-acute; IMOS, Integrative Medicine Outcome Scale; IMPSS, Integrative Medicine Patient Satisfaction Scale

Study Drug and Placebo

GHX02 is a combination of the following four herbs: Gwaruin (*Trichosanthis Semen*, 351 mg/tablet), Haengin (*Armeniacae Semen*, 175.5 mg/tablet), Hwangryeon (*Coptidis Rhizoma*, 175.5 mg/tablet), Hwangkeum (*Scutellariae Radix*, 351 mg/tablet) (Table 1). One GHX02 tablet (500mg/tablet) contains 160.0mg of dry extract of the four herbs (obtained by boiling in water and then dehydrating) mixed with 340.0mg of starch and lactose. The placebo tablet does not contain any of these active ingredients but is matched in terms of colour, smell, and taste. The dosage was determined according to the Pharmacologically Active Dose (PAD) in expectorant effective tests. Both tablets are pink and round and will be provided by Hankookshinyak Corporation (Nonsan, Korea). The manufacturer complies with the provisions of the Regulations on the Safety of Pharmaceuticals and will manage the quality appropriately. Safety and toxicological tests of GHX02 will be conducted simultaneously. All allocated patients will be prescribed 4 tablets of either the clinical medicine or placebo to be administered three times daily for 7 days, and the number of remaining tablets will be recorded on day 7 to calculate compliance. To improve compliance, participants will be asked to record their daily dosage in the cough diary. The overall medication compliance during the trial should be at least 75%; if the medication compliance is less than 75%, the participant will be considered inadequate and excluded from the per-protocol (PP) analysis group.

Sample size

The estimated sample size required for this study is 150 patients (50 patients per group).¹⁹ The

1
2
3
4 estimation of the number of subjects is based on whether there is a difference in the change from
5 baseline (day 0) to post-dose (day 7) BSS, between the control and standard-dose GHX02 group.
6
7 In an earlier comparable clinical study, the difference was reported to be 2.3, and the standard
8 deviation of the changes in BSS, was estimated to be 3.2.²⁰ The power to detect the difference
9 was assumed to be 0.8, and the two-sided significance level was 0.05. The ratio of allocation of
10 subjects between the groups was 1:1:1, and dropout rate was presumed to be 0.2.
11
12
13
14
15

16 **Recruitment**

17
18
19 Participants will be recruited from the outpatient departments (OPDs) of the affiliated hospitals by
20 posting brochures in a well visible place in front of the clinic and distributing it to every patient
21 visiting OPDs of pulmonology. Recruitment will commence in January 2018.
22
23
24
25

26 **Participants**

27 Inclusion criteria

28
29
30
31 Potential participants who meet the following criteria will be included in this trial: (1) age 19–75
32 years; (2) BSS \geq 5 points at day 0 due to acute bronchitis; (3) symptoms starting within 2 weeks
33 before study inclusion; (4) patients who consent to participate. Diagnoses of acute bronchitis will
34 be based on patients' medical history, physical examinations, and BSS, including cough, sputum,
35 dyspnea, chest pain during coughing, and rales on auscultation.
36
37
38
39
40
41

42 Exclusion criteria

43
44
45 Patients with any of the following criteria will be excluded from this trial: (1) pregnant or breast-
46 feeding; (2) treatment with antibiotics, bronchodilators, glucocorticoids, immune-depressants, or
47 other clinical trial medicines during the last 4 weeks before study inclusion; (3) treatment with
48 antitussives or expectorants during the last 7 days before study inclusion; (4) history or presence
49 of confounding respiratory disease that may affect evaluation of the efficacy of clinical medicine
50 (e.g. chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, asthma,
51
52
53
54

1
2
3
4 pneumonia, cystic fibrosis, lung cancer, or active pulmonary tuberculosis); (5) liver or renal
5 impairment (alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline
6 phosphatase [ALP] ≥ 2 times the normal upper limit, or creatinine > 3.0 mg/dL at screening); (6)
7 history or presence of clinically relevant cardiovascular, renal, metabolic, haematological,
8 neurological, psychiatric, systemic, infectious disease, or malignant tumour (except where there is
9 no recurrence for more than 5 years after surgery); (7) genetic problems such as galactose
10 intolerance, Lapp lactose deficiency or glucose-galactose malabsorption; (8) history of alcoholism
11 or substance abuse; (9) participation in other clinical medicine trials during the last 30 days before
12 study inclusion; (10) judged by the investigators to be inappropriate for the clinical trial.
13 Additional treatment will not be permitted during the trial, and participants are recommended not
14 to alter their exercise pattern or diet. Drugs that may affect bronchitis symptoms or that have a
15 similar therapeutic purpose to the trial medication will not be permitted, including antibiotics,
16 bronchodilators, glucocorticoids, immune-depressants, antitussives, expectorants or any other
17 clinical trial medicine. Those who require or take these concomitant medicines during the trial will
18 be excluded from this study. Other medications will only be permitted at the discretion of the
19 investigators. All drug information (name of product, purpose of administration, dosage, duration
20 of administration, etc.) will be recorded on the patient case report form (CRF).
21
22
23
24
25
26
27
28
29
30
31
32
33

34 Randomization and allocation concealment

35
36 An independent statistician will conduct randomization, using a computer random number
37 generator of SAS[®] Analytics Pro (SAS Institute, Inc., Cary, North Carolina, USA). Allocation will be
38 implemented by the manufacturers who collectively label participant's identification code on the
39 packages of the test drug or a placebo using generated random numbers. This labeled drug will
40 be given to the management pharmacist. When the investigator requests medication, the
41 management pharmacist gives the participant the drug corresponding to the participant's
42 identification code. Only the statistician and manufacturer have access to the random numbers,
43 and they will sign and submit a written non-disclosure agreement. After that, just the
44 identification code is used to identify which drug to give to which participant. We will allocate
45 three groups (*wind-heat*, *wind-cold*, or *others*) at a 1:1:1 ratio of high-dose, standard-dose, and
46 placebo treatment. Stratified block randomization using the Korean Standard Tool of Pattern
47 Identifications of Cough and Sputum will be performed in this trial.
48
49
50
51
52
53
54

Korean Standard Tool of Pattern Identifications of Cough and Sputum

The Korean Standard Tool of Pattern Identifications of Cough and Sputum is used to identify patterns of acute bronchitis patients. This pattern identification is an important diagnostic criterion in Korean medicine which is used for deciding medication and other therapies. It was proposed in the Traditional Korean Medicine Clinical Practice Guidelines for Antitussives and Expectorants for Korean Medical Diagnostic Standards.²¹ This comprises 56 items to classify cases into three patterns: *wind-cold*, *wind-heat* or *others*. We will investigate the correlation between the patterns and the efficacy of GHX02; the *wind-heat* patterns group is expected to show greater response than the other groups to the therapeutic effects of GHX02.

Blinding

This is a double-blind trial, thus neither participants nor investigators (including outcome assessors) will be aware of group assignment until the end of the study period. Placebo tablets will be matched to GHX02 tablets in terms of colour, taste, and smell, as well as outer packaging. Elimination of blindness will only be considered in cases of serious medical emergencies.

Outcome measures

Primary outcome

Bronchitis Severity Score

The BSS was developed as an evaluation tool for acute bronchitis in 1996 and was recently shown to be valid and reliable by the European Medicines Agency's Committee on Herbal Medicinal Products (HMPC).²⁰ It has been used successfully in many clinical trials for acute bronchitis. BSS comprises the sum of five major symptom scores for acute bronchitis: cough, sputum, dyspnea, chest pain during coughing, and rales on auscultation. Each symptom is scored on a 4-point-scale (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe), with a maximum total score of 20 points. The investigator assesses symptom scores on the basis of the patient's subjective

1
2
3
4 symptoms, and this correlates highly with the patient's actual improvement, as acute bronchitis
5 mainly involves subjective complaints.²² The change in BSS between day 0 and day 7 will be the
6 primary outcome of this trial.
7
8
9

10 11 12 Secondary outcomes

13
14 Assessment of acute bronchitis predominantly depends on subjective tools, but more reliable data
15 can be derived if appropriate objective variables are used together. Symptom and quality of life
16 (QOL) questionnaires will be used as subjective tools, whereas cough frequency will be used as an
17 objective tool; among outcome measures of cough symptoms, only cough frequency and quality
18 of life questionnaires have been shown to be valid.²³
19
20
21
22
23
24

25 *Questionnaire of Clinical Symptoms of Cough and Sputum*

26
27 The Questionnaire of Clinical Symptoms of Cough and Sputum (QCSCS) was proposed as a
28 primary outcome measure in the Traditional Korean Medicine Clinical Practice Guidelines for
29 Antitussives and Expectorants²¹ and was developed by remodelling the Clinical Asthma
30 Measurement Scale in Oriental Medicine-V for cough and sputum.²⁴ It is also appropriate for
31 preparing clinical trials of GHX02 as an Investigational New Drug (IND), as it is the suggested tool
32 in Clinical Practice Guidelines from the Ministry of Food and Drug Safety in Korea. Questionnaire
33 items are as follows: (1) cough – frequency, intensity, sensitivity; (2) sputum – frequency, volume,
34 difficulty to cough-up, appearance, colour; (3) activities of daily living; (4) night-time sleeping.
35 Each item is scored on a 4-point-scale, with a total maximum score of 40 points. This
36 questionnaire can evaluate symptoms of cough and sputum more specifically and in more detail
37 than the BSS. The changes in QCSCS from day0 to day7 will be analysed for a secondary outcome.
38
39
40
41
42
43
44
45
46
47

48 *Leicester Cough Questionnaire*

49
50 The Leicester Cough Questionnaire (LCQ-K-acute) evaluates quality of life associated with cough. It
51 consists of 19 items divided into three parts, physical, psychological, and social, each scored from
52 1 to 7. The total score is the sum of the average scores (1–7 points) for each part. The higher the
53
54

score, the better the quality of life. Although it was initially developed as an assessment tool for chronic cough, it has also been found to be useful for acute cough, by changing the time criteria from 2 weeks to 24 hours.²⁵ In addition, the validity and reliability of the Korean version of the LCQ(LCQ-K) has already been verified.²⁶ The changes of LCQ-K-acute between day0 and day7 will be evaluated.

Frequency of coughing fits

Coughing frequency is an objective measurement tool for evaluating coughing. In this trial, we will ask participants to record how often they cough each day. A cough diary will be given to record their everyday coughing frequency, and participants will be classified into one of the following scales: 0 = 0 time/day, 1 = 1 time/day, 2 = 2-3 times/day, 3 = 4-5 times/day(sometimes), 4 = 6-10 times/day(frequent), 5 = over 15 times/day(consistently).²⁷ We will evaluate the frequency of coughing fits daily from day0 to day7 and analyse the changes in frequency of coughing fits after 1-7days from the baseline. (change in frequency of coughing fits after k days of study = frequency of coughing fits after k days of study - frequency of coughing fits at day0, where k = 1, 2, ..., 7)

Integrative Medicine Outcome Scale and Integrative Medicine Patient Satisfaction Scale

The Integrative Medicine Outcome Scale is a 5-point-scale for evaluating improvement after treatment (where, 1=complete recovery, 2=major improvement, 3=slight-to-moderate improvement, 4=no change, 5=deterioration), either by the patient or investigator (the investigator in this trial). The Integrative Medicine Patient Satisfaction Scale is a 5-point-scale for evaluating patient satisfaction with the treatment (where, 1=very satisfied, 2=satisfied, 3=neutral, 4=dissatisfied, 5=very dissatisfied).²⁰ Both will be measured at the patients' final visit (day7) and will be analysed for a secondary outcome.

Withdrawal rate of patients with exacerbation

Exacerbation in this trial means progression of acute bronchitis to bacterial bronchitis or

1
2
3
4 pneumonia, requiring concomitant medicine such as antibiotics, bronchodilators, glucocorticoids,
5 etc. During the trial, patients will be asked to inform about any signs of worsening symptoms, and
6 investigators will evaluate appropriate measures if they need additional therapy. Those who
7 require concomitant medicines will be excluded from the trial and provided the necessary
8 medicine. We will calculate this withdrawal rate in each intervention and control group to check
9 the relevance with drug effects.
10
11
12
13
14
15

16 **Safety assessment**

17
18 Safety will be assessed in terms of adverse events (AEs), vital signs, and laboratory examinations
19 (liver function test and routine blood and urine tests). AEs and vital signs will be recorded on a
20 CRF at every visit, and laboratory examinations will be conducted before and after taking the
21 medication. AEs are defined as every unexpected sign or symptom during the trial period and
22 participants are asked to inform about any of these AEs during medication. All information about
23 AEs will be recorded in detail, such as the duration and extent of the AE, relationship with the trial
24 medicine, name of the suspected drug, etc. Common adverse events may include gastrointestinal
25 side-effects, such as anorexia, stomach discomfort, nausea, and diarrhoea, which are not expected
26 to be severe. However, if serious AEs occur that may lead to death or require extended
27 hospitalization, the patient will be removed from the clinical trial as soon as possible and proper
28 treatment will be provided (Table2).
29
30
31
32
33
34
35
36
37
38

39 **Data management and monitoring**

40
41 The investigators will follow the Standard Operating Procedures (SOP) of the trial for a better
42 quality of assessment and collection of outcome data. The investigators who evaluate outcome
43 measures should be restricted to only physicians who have attended the training meetings. All
44 assessment data and case reports will be collected at baseline (day0) and at the end of the trial
45 (day7) in both the intervention and control groups. Collected documents and data will be
46 managed by electronic CRF and encrypted using double data entry. Only the principle investigator,
47 or those who have permission, will be able to access the data. The CRFs and other documents will
48 be stored at a separate and secure location for 10 years after trial completion.
49
50
51
52
53
54

Multicentre clinical trial monitoring will be conducted via regular visits (every one-fourth of recruitment) and occasional telephone calls. The information collected will be reported to the data monitoring committee (DMC), comprising specialists in pulmonology and medical statistics who are unrelated to this trial. At visits, a monitor will confirm whether the trial is being conducted in accordance with the protocol and especially AEs are being properly reported and recorded on CRFs. The monitor will check the whole process of the clinical trial and problems will be discussed with the investigator as and when they occur.

Statistical analysis

Data analysis will be performed by an independent statistician using SAS[®] Analytics Pro. Continuous variables will be summarized by Mean \pm SD, and categorical variables will be reported with frequencies and percentages according to three treatment groups. Efficacy evaluation will be primarily based on the intention-to-treat (ITT) analysis, and per-protocol (PP) analysis will be used as a secondary analysis. ITT analysis will be conducted for all subjects randomized, and PP analysis will be conducted for those who completed the entire trial without violating the protocol. For primary outcome analysis, the changes in BSS between day0 and day7 will be evaluated using analysis of covariance (ANCOVA) which contains the day0's BSS and the treatment group as covariates. Significance will be accepted at a two-sided test with α -level of 0.05. For effects of GHX02 treatments compared with the control group, 95% confidence intervals (CIs) will be calculated. Analyses of secondary outcomes will be carried out as follows: QCSCS and LCQ-K-acute by ANCOVA including its baseline value respectively; frequency of coughing fits by linear mixed models (LMMs); IMOS and IMPSS by analysis of variance (ANOVA); and withdrawal rate of patients with exacerbation by Pearson's chi-squared or Fisher's exact tests. To handle missing values when processing ITT analysis, the last-observation-carried-forward (LOCF) method will be used except for frequency of coughing fits analysed with LMMs in which missing values need not to be imputed.

Safety assessment will be performed by ITT analysis; all participants randomized will be included. Comparison of the number of adverse events between three treatment groups will be performed using Kruskal-Wallis tests. Demographic and baseline data will be analysed using ANOVA for continuous variables, and Pearson's chi-squared or Fisher's exact tests for categorical variables.

Patient and Public Involvement

Patients and public are not actively involved in the process of this study. The participants will be informed of the study results via peer-reviewed journals, conference and the Clinical Research Information Service.

ETHICS AND DISSEMINATION

The trial protocol (version 1.0) has been approved by the Institutional Review Board (IRB) of the Dunsan Korean Medicine Hospital, Daejeon University (No. DJDSKH-17-DR-14) and has been registered through the clinical trials registry (NCT03310385). If the protocol needs modifications, the investigators are required to inform the IRB (as well as participants) and receive re-approval. Before the trial, investigators are required to provide all information related to the clinical trial, including the possible benefits and risks, other therapeutic choices, and right to withdraw, via a written consent form approved by the IRB. After being provided with sufficient time and opportunity to ask questions and decide whether to participate, all participants are required to provide written consent before study inclusion. All patient identifiable data will be kept confidential, even when the results of the trial are published and participant information will be stored in a secure file, and only the primary investigator (including those who have permission) and the monitor will have access to the data. To ensure confidentiality, all clinical trial documents, such as CRFs, will be recorded and distinguished by the participant identification number throughout the trial. At the end of the trial, the study results will be disseminated via peer-reviewed journals, conference presentation and the Clinical Research Information Service; the participants will also be informed of the results, even unpublished data, including missing data.

DISCUSSION

Despite problems associated with antibiotic abuse in public health systems and the substantial economic burden associated with acute bronchitis, currently no definitive medication is recommended. There are many studies exploring the efficacy of herbal medicines; a systematic review concluded that there was insufficient evidence to support the use of Chinese herbs for acute bronchitis because of the high risk of bias and lack of toxicological evidence.¹² This study is

1
2
3
4 a multicentre, double-blind, randomized placebo-controlled trial to evaluate the efficacy and
5 safety of two different doses of GHX02, compared with placebo, for acute bronchitis, and we
6 followed strict quality control methods. To ensure a well-designed trial, we conducted a systematic
7 review of randomized controlled trials for acute bronchitis in the last 10 years.²⁸
8
9

10
11 There are some strengths and limitations to this protocol. Contrary to other trials, we will use the
12 Korean Standard Tool of Pattern Identifications of Cough and Sputum, which is a Korean Medical
13 Diagnostic Standard for categorizing cases, to obtain additional information as to whether a
14 certain categories of patients respond better than others to treatment. In this way, we will be able
15 to investigate the efficacy of GHX02 for more specific categories of people suffering from acute
16 bronchitis. Another strength is that the outcome measures we will use in this trial is well balanced
17 between patients' subjective and objective outcomes; thus, the effectiveness of GHX02 will be
18 demonstrated from various aspects. As GHX02 is an herbal prescription which has already been
19 used for acute bronchitis, there is little risk of side-effects and the efficacy of GHX02 is already
20 proven by empirical evidence. This study will provide new evidence for the efficacy and safety of
21 GHX02 in a standard research design and is expected to be presented as a recommended
22 alternative medicine for acute bronchitis.
23
24
25
26
27
28
29

30 A limitation of this trial protocol is that we will only target adults, despite most acute bronchitis
31 patients being children under 5 years. As clinical drug trials are recommended to be first applied
32 to adults, we selected adults aged between 19 and 75 years. Further studies for children will need
33 to be conducted after completion of this study.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

Author affiliations

- 1 Division of Respiratory System, Dept. of Internal Medicine, College of Korean Medicine, Daejeon University
- 2 East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University
- 3 Institute of Traditional Medicine and Bioscience, Daejeon University
- 4 Dept. of Applicative Statistics, College of Economics, Daejeon University
- 5 Dept. of Neuropsychology, College of Korean Medicine, Daejeon University

Acknowledgements

The authors thank the staff and patients participating in the study. Additionally, the authors thank the staff at Daejeon University Dunsan Korean Medicine Hospital Clinical Trial Center (DCTC), especially Da Yeong Lee for overview of the research. We also thank Ju Ah Lee for writing and drawing up the protocol.

Contributors

YRL drafted the research protocol and wrote the manuscript. WKY, SJP, SHK were involved in the protocol development. WK contributed to the statistical design and analysis. ICJ and YCP supervised this protocol. All authors contributed to the conception and implementation of this clinical trial.

Funding

This research was supported by the National Research Foundation of Korea Grant funded by the Korean Government (NRF-2015R1D1A1A01058852), the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (grant number: HI15C0006), and Korea Institute of Oriental Medicine (grant number: K17510).

Competing interests

None declared.

Ethics approval

The protocol was approved by the Institutional Review Board of Dunsan Korean Medicine Hospital, Daejeon University.

Provenance and peer review

Not commissioned; externally peer reviewed.

REFERENCES

1. Wenzel RP, Fowler III AA. Acute bronchitis. *New England journal of medicine* 2006;355(20):2125-30.
2. Park MJ, Rhee CK, Kim YH, et al. Efficacy and safety of HL301 in the treatment of acute bronchitis and acute exacerbation of chronic bronchitis: a phase 2, randomized, double-blind, placebo-controlled, multicenter study. *Current Medical Research and Opinion* 2017;33(5):919-25.
3. Kamin W, Ilyenko LI, Malek FA, et al. Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents. *Pediatrics International* 2012;54(2):219-26.
4. Tackett KL, Atkins A. Evidence-based acute bronchitis therapy. *Journal of pharmacy practice* 2012;25(6):586-90.
5. Kinkade S, Long NA. Acute Bronchitis. *American family physician* 2016;94(7)
6. Albert RH. Diagnosis and treatment of acute bronchitis. *American family physician* 2010;82(11)
7. Steinman MA, Sauaia A, Maselli JH, et al. Office evaluation and treatment of elderly patients with acute bronchitis. *Journal of the American Geriatrics Society* 2004;52(6):875-79.
8. Smith SM, Smucny J, Fahey T. Antibiotics for acute bronchitis. *Jama* 2014;312(24):2678-79.
9. Braman SS. Chronic cough due to acute bronchitis: ACCP evidence-based clinical practice guidelines. *CHEST Journal* 2006;129(1_suppl):95S-103S.
10. Smith SM, Schroeder K, Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings. *Cochrane Database Syst Rev* 2012;8(8)
11. Cayley Jr WE. Beta2 Agonists for Acute Cough or a Clinical Diagnosis of Acute Bronchitis. *American family physician* 2017;95(9):551.
12. Jiang L, Li K, Wu T. Chinese medicinal herbs for acute bronchitis. *The Cochrane Library* 2012
13. Timmer A, Günther J, Motschall E, et al. Pelargonium sidoides extract for treating acute respiratory tract infections. *The Cochrane Library* 2013
14. Holzinger F, Chenot J-F. Systematic review of clinical trials assessing the effectiveness of ivy leaf (*hedera helix*) for acute upper respiratory tract infections. *Evidence-Based Complementary and Alternative Medicine* 2010;2011
15. Castro M. Placebo versus best-available-therapy control group in clinical trials for pharmacologic therapies: which is better? *Proceedings of the American Thoracic Society* 2007;4(7):570-73.
16. Moher D, Chan AW. SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials). *Guidelines for Reporting Health Research: A User's Manual* 2014:56-67.
17. Cheng C-w, Wu T-x, Shang H-c, et al. CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration. *Annals of internal medicine* 2017;167(2):112-21.

18. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMC medicine* 2010;8(1):18.
19. Chow S, Shao J. Wang, Sample Size Calculations In Clinical Research: Taylor & Francis, NY, 2003.
20. Matthys H, Kamin W. Positioning of the Bronchitis Severity Score (BSS) for standardised use in clinical studies. *Current medical research and opinion* 2013;29(10):1383-90.
21. Ministry of Food and Drug Safety, Herbal medicine Evaluation Department. The Traditional Korean Medicine Clinical Practice Guidelines for Antitussives and Expectorants. Seoul: Ministry of Food and Drug Safety 2007:5-15.
22. Lehl S, Matthys H, Kamin W, et al. The BSS—a valid clinical instrument to measure the severity of acute bronchitis. *Pulm Respir Res* 2014;1:00016.
23. Leconte S, Ferrant D, Dory V, et al. Validated methods of cough assessment: a systematic review of the literature. *Respiration* 2011;81(2):161-74.
24. Baek H-j, Lee B-j, Jung S-k, et al. Retrospective Study of Patients with Cough Treated with Eunhwayeongyo-tang. *The Journal of Internal Korean Medicine* 2016;37(6):961-77.
25. Yousaf N, Lee KK, Jayaraman B, et al. The assessment of quality of life in acute cough with the Leicester Cough Questionnaire (LCQ-acute). *Cough* 2011;7(1):4.
26. Han J-M, Jung I-C, Kang W, et al. Reliability and validity of leicester cough questionnaire Korean version. *Chronic respiratory disease* 2014;11(3):147-52.
27. Fischer J, Dethlefsen U. Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial. *Cough* 2013;9(1):25.
28. Lyu Y, Lee EJ, Jeon JH, et al. A Systemic Review of Clinical Trials Using Medication for Acute Bronchitis: A Pre-study on the Development of Traditional Korean Medicine Clinical Practice Guideline. *Journal of Korean Medicine* 2017;38(1):93-111.

FIGURE LEGENDS

Figure 1. Flowchart of the study procedure




Figure1. Flowchart of the study procedure

Figure1. Flowchart of the study procedure

81x60mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	p.1,line1-3
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	p.2,line26/ p.14,line5
	2b	All items from the World Health Organization Trial Registration Data Set	p.5,line8-12
Protocol version	3	Date and version identifier	p.14,line2
Funding	4	Sources and types of financial, material, and other support	p.16,line18-22
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	p.16,line13-16
	5b	Name and contact information for the trial sponsor	p.16,line18-22
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	-
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	p.14,line1-4

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47**Introduction**

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	p.3,line10-p.4,line16
	6b	Explanation for choice of comparators	p.4,line14-16
Objectives	7	Specific objectives or hypotheses	p.4,line12-14
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	p.4,line27-29

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	p.4,line29-p.5,line2, p.7,line9-11
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	p.7,line13-p.8,line18
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	p.6,line22-24
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	p.8,line10-14/ p9,line15/ p11,line25-p.12,line4
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	p.6,line25-26
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	p.8,line10-16
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	p.9,line18-p.12,line4

1				
2				
3	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	p.5,line13-p.6,line9
4				
5	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	p.6,line30-p.7,line5
6				
7				
8	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	p.7,line7-10
9				
10				

11 **Methods: Assignment of interventions (for controlled trials)**

12 Allocation:

13				
14				
15	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	p.8,line19-20/25-27/29-30
16				
17				
18				
19				
20	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	p.8,line20-23
21				
22				
23				
24	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	p.8,line23-27
25				
26				
27	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	p.9,line12-13
28				
29				
30		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	p.9 ,line15
31				
32				
33				

34 **Methods: Data collection, management, and analysis**

35				
36	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	p.12,line20-24
37				
38				
39				
40				
41				
42				

1			
2			
3		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols
4			p.6,line25-26
5			
6	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol
7			p.12,line24-26
8			
9			
10	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol
11			p.13,line10-21
12			
13		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)
14			p.13,line18-21
15		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)
16			p.13,line21-24
17			
18	Methods: Monitoring		
19			
20	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed
21			p.12,line28-p.13,line5
22			
23			
24			
25		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial
26			p.12,line15-17/ p.11,line25-p.12,line4
27			
28	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct
29			p.12,line11-17 / p.13,line2-4
30			
31	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor
32			p.12,line28-p.13,line5
33			
34			
35	Ethics and dissemination		
36			
37	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval
38			p.14,line2-4
39			
40			
41			
42			
43			
44			
45			
46			
47			

1				
2				
3	Protocol	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes,	p.14,line4-5
4	amendments		analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals,	
5			regulators)	
6				
7	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and	p.14,line6-10
8			how (see Item 32)	
9				
10		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary	p.14,line6-10
11			studies, if applicable	
12				
13	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained	p.14,line10-15
14			in order to protect confidentiality before, during, and after the trial	
15				
16	Declaration of	28	Financial and other competing interests for principal investigators for the overall trial and each study site	p.16,line24-25
17	interests			
18				
19	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that	p.14,line12-13
20			limit such access for investigators	
21				
22	Ancillary and post-	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial	p.12,line15-17
23	trial care		participation	
24				
25	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals,	p.14,line15-17
26			the public, and other relevant groups (eg, via publication, reporting in results databases, or other data	
27			sharing arrangements), including any publication restrictions	
28				
29		31b	Authorship eligibility guidelines and any intended use of professional writers	p.16,line13-16
30				
31		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	p.14,line15-17
32				
33	Appendices			
34				
35	Informed consent	32	Model consent form and other related documentation given to participants and authorised surrogates	-
36	materials			
37				
38	Biological	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular	p.12,line26-27
39	specimens		analysis in the current trial and for future use in ancillary studies, if applicable	
40				
41				
42				
43				
44				
45				
46				
47				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

For peer review only